PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:		(11) International Publication Number: WO 93/0316
C12N 15/83, C12P 21/02	A1	(43) International Publication Date: 18 February 1993 (18.02.9
Filed on 22 October 1990 US 641, Filed on 16 January 1991 US 737, Filed on 26 July 1991	(31.07.9 244 (Cl) (22.10.9 617 (Cl) (16.01.9 619 (Cl) (26.07.9 143 (Cl) (01.09.9 1US/US (US/US) (US/US) 88 (US)	(74) Agents: HALLUIN, Albert, P. et al.; Limbach & Limbach 2001 Ferry Building, San Francisco, CA 94111 (US). (81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JI KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, U, European patent (AT, BE, CH, DE, DK, ES, FR, GI GR, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CI CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published With international search report. SI; O7, SI; O8, SI; O8, SI; O9, SI;

(54) Title: RECOMBINANT PLANT VIRAL NUCLEIC ACIDS

(57) Abstract

The present invention is directed to recombinant plant viral nucleic acids and to hosts infected thereby. The recombinant plant viral nucleic acids comprise a native plant viral subgenomic promoter, at least one non-native plant viral subgenomic promoter, a plant viral coat protein coding sequence, and optionally, at least one non-native nucleic acid sequence to be transcribed or expressed in the infected host plant. The recombinant plant viral nucleic acids are stable, capable of systemic infection and capable of stable transcription or expression in the plant host of the non-native nucleic acid sequences.



04/11/2003, EAST Version: 1.03.0002

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	Fi	Finland	MN	Mongolia
AU	Australia	FR	France	MR	Mauritania
BB	Barbados	GA	Gabon	MW	Malawi
BE	Belgium	GB	United Kingdom	NL	Netherlands
BF	Burkina Faso	GN	Guinea	NO .	Norway
BG	Bulgaria	GR	Greece	NZ	New Zealand
_	Benin	HU	Hungary	PL	Poland
BJ		IE	Ireland	PŤ	Portugal
BR	Brazil	iT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
Œ	Central African Republic	KP	Democratic People's Republic	SD	Sudan
œ	Cungo	KP	• •	SE	Sweden
CH	Switzerland		of Korca	SK	Slovak Republic
CI	Côte d'Ivoire	KR	Republic of Korea		•
CM	Cameroon	LI	Liechtenstein	SN	Senegal
CS	Czechoslovakia	LK	Sri Lanka	รบ	Soviet Union
CZ	Czech Republic	LU	Laxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denniark	MG	Madagascar	UA	Ukraine
ES	Spain	Ml.	Mali	us	United States of America

TITLE OF THE INVENTION

٤

RECOMBINANT PLANT VIRAL NUCLEIC ACIDS

BACKGROUND OF THE INVENTION

The present invention relates to plant viral vectors which are (a) self-replicating; (b) capable of systemic infection in a host; (c) contain, or are capable of containing, nucleic acid sequences foreign to the native virus, which are transcribed or expressed in the host plant; and (d) stable, especially for the transcription and expression of foreign nucleic acid sequences.

Viruses are a unique class of infectious agents whose distinctive features are their simple organization and their mechanism of replication. In fact, a complete viral particle, or virion, may be regarded mainly as a block of genetic material (either DNA or RNA) capable of autonomous replication, surrounded by a protein coat and sometimes by an additional membranous envelope such as in the case of alpha viruses. The coat protects the virus from the environment and serves as a vehicle for transmission from one host cell to another.

Unlike cells, viruses do not grow in size and then divide, because they contain within their coats few (or none) of the biosynthetic enzymes and other machinery required for their replication. Rather, viruses multiply in cells by the synthesis of their separate components, followed by assembly. Thus, the viral nucleic acid, after shedding its coat, comes into contact with the appropriate cell machinery where it specifies the synthesis of proteins required for viral reproduction. The viral nucleic acid is

ŝ

7

then itself replicated through the use of both viral and cellular enzymes. The components of the viral coat are formed and the nucleic acid and coat components are finally assembled. With some viruses, replication is initiated by enzymes present in virions.

A given plant virus may contain either DNA or RNA, which may be either single- or double-stranded. The portion of nucleic acid in a virion varies from about 1% to about 50%. The amount of genetic information per virion varies from about 3 kb to 300 kb per strand. The diversity of virus-specific proteins varies accordingly. One example of doublestranded DNA containing plant viruses includes, but is not limited to, caulimoviruses such as Cauliflower mosaic virus (CaMV). Representative plant viruses which contain single-stranded DNA are Cassava latent virus, bean golden mosaic virus (BGMV), and Chloris striate mosaic virus. Rice dwarf virus and wound tumor virus are examples of double-stranded RNA plant viruses. Single-stranded RNA plant viruses include tobacco mosaic virus (TMV), turnip yellow mosaic virus (TYMV), rice necrosis virus (RNV) and brome mosaic virus (BMV). The RNA in single-stranded RNA viruses may be either a plus (+) or a minus (-) strand. For general information concerning plant viruses, see Grierson, D. et al. (1); Gluzman, Y. et al. (2).

One means for classifying plant viruses is based on the genome organization. Although many plant viruses have RNA genomes, organization of genetic information differs between groups. The genome of most monopartite plant RNA viruses is a single-stranded molecule of (+)- sense. There are at least 11 major groups of viruses with this type of genome.

An example f this type of virus is TMV. At least six major groups of plant RNA viruses have a bipartite genome. In these, the genome usually consists of two distinct (+) - sense single-stranded RNA molecules encapsidated in separate particles. Both RNAs are required for infectivity. Cowpea mosaic virus (CPMW) is one example of a bipartite plant virus. A third major group, containing at least six major types of plant viruses, is tripartite, with three (+) - sense single-stranded RNA molecules. Each strand is separately encapsidated, and all three are required for infectivity. An example of a tripartite plant virus is alfalfa mosaic virus (AMV). Many plant viruses also have smaller subgenomic mRNAs that are synthesized to amplify a specific gene product. One group of plant viruses having a single-stranded DNA genome are the geminiviruses, such as Cassava latent virus (CLV) and maize streak virus (MSV). Several plant viruses have been cloned to study their nucleic acid, in anticipation of their use as plant transformation vectors. Examples of viruses cloned include BMV, Ahlguist, P. and Janda, M. (3); TMV, Dawson W.O. et al. (4); CaMV, Lebeurier, G. et al. (5); and BGMV, Morinaga, T. et al. (6).

Techniques have been developed which are utilized to transform many species of organisms. Hosts which are capable of being transformed by these techniques include bacteria, yeast, fungus, animal cells and plant cells or tissue. Transformation is accomplished by using a vector which is self-replicating and which is compatible with the desired host. The vectors are generally based on either a plasmid or a virus. Foreign DNA is inserted into the vector, which is then used to transform the

appropriate host. The transformed host is then identified by selection or screening. For further information concerning the transformation of these hosts, see <u>Molecular Cloning</u> (7) <u>DNA Cloning</u> (8); Grierson, D. et al. (1), and <u>Methods in Enzymology</u>, (9).

Viruses that have been shown to be useful for the transformation of plant hosts include CaV, TMV and BV. Transformation of plants using plant viruses is described in US 4,855,237 (BGV), EP-A 67,553 (TMV), Japanese Published Application No. 63-14693 (TMV), EPA 194,809 (BV), EPA 278,667 (BV), Brisson, N. et al. (10) (CaV), and Guzman et al. (2). Pseudovirus particles for use in expressing foreign DNA in many hosts, including plants, is described in WO 87/06261.

When the virus is a DNA virus, the constructions can be made to the virus itself. Alternatively, the virus can first be cloned into a bacterial plasmid for ease of constructing the desired viral vector with the foreign DNA. The virus can then be excised from the plasmid. If the virus is a DNA virus, a bacterial origin of replication can be attached to the viral DNA, which is then replicated by the bacteria. Transcription and translation of this DNA will produce the coat protein which will encapsidate the viral DNA. If the virus is an RNA virus, the virus is generally cloned as a cDNA and inserted into a plasmid. The plasmid is then used to make all of the constructions. The RNA virus is then produced by transcribing the viral sequence of the plasmid and translation of the viral genes to produce the coat protein(s) which encapsidate the viral RNA.

Construction of plant RNA viruses for the introduction and expression of non-viral foreign

genes in plants is d monstrated by the above references as well as by Dawson, W.O. et al. (11); Takamatsu, N. et al. (12); French, R. et al. (13); and Takamatsu, N. et al. (14). However, none of these viral vectors have been capable of systemic spread in the plant and expression of the non-viral foreign genes in the majority of the plant cells in the whole plant. Another disadvantage of many of the prior art viral vectors is that they are not stable for the maintenance of non-viral foreign genes. for example, Dawson, W.O. et al. (11),. Thus, despite all of this activity to develop plant viral vectors and viruses, a need still exists for a stable recombinant plant virus capable of systemic infection in the host plant and stable expression of the foreign DNA.

SUMMARY OF THE INVENTION

The present invention is directed to recombinant plant viral nucleic acids and recombinant viruses which are stable for maintenance and transcription or expression of non-native (foreign) nucleic acid sequences and which are capable of systemically transcribing or expressing such foreign sequences in the host plant. More specifically, recombinant plant viral nucleic acids according to the present invention comprise a native plant viral subgenomic promoter, at least one non-native plant viral subgenomic promoter, a plant viral coat protein coding sequence, and optionally, at least one non-native, nucleic acid sequence.

In one embodiment, a plant viral nucleic acid is provided in which the native coat protein coding sequence has been deleted from a viral nucleic acid,

a non-native plant viral coat protein coding sequence and a non-native promoter, preferably the subgenomic promoter of the non-native coat protein coding sequence, capable of expression in the plant host, packaging of the recombinant plant viral nucleic acid, and ensuring a systemic infection of the host by the recombinant plant viral nucleic acid, has been inserted.

The recombinant plant viral nucleic acid may contain one or more additional non-native subgenomic promoters. Each non-native subgenomic promoter is capable of transcribing or expressing adjacent genes or nucleic acid sequences in the plant host and incapable of recombination with each other and with native subgenomic promoters.

Non-native (foreign) nucleic acid sequences may be inserted adjacent the native plant viral subgenomic promoter or the native and a non-native plant viral subgenomic promoters if more than one nucleic acid sequence is included. The non-native nucleic acid sequences are transcribed or expressed in the host plant under control of the subgenomic promoter to produce the desired products.

In a second embodiment, a recombinant plant viral nucleic acid is provided as in the first embodiment except that the native coat protein coding sequence is placed adjacent one of the non-native coat protein subgenomic promoters instead of a non-native coat protein coding sequence.

In a third embodiment, a recombinant plant viral nucleic acid is provided in which the native coat protein gene is adjacent its subgenomic promoter and one or more non-native subgenomic promoters have been inserted into the viral nucleic acid. The inserted non-native subgenomic promoters are capable of

transcribing or expressing adjacent genes in a plant host and are incapable of recombination with each other and with native subgenomic promoters. Non-native nucleic acid sequences may be inserted adjacent the non-native subgenomic plant viral promoters such that said sequences are transcribed or expressed in the host plant under control of the subgenomic promoters to produce the desired product.

In a fourth embodiment, a recombinant plant viral nucleic acid is provided as in the third embodiment except that the native coat protein coding sequence is replaced by a non-native coat protein coding sequence.

The viral vectors are encapsidated by the coat proteins encoded by the recombinant plant viral nucleic acid to produce a recombinant plant virus. The recombinant plant virual nucleic acid or recombinant plant virus is used to infect appropriate host plants. The recombinant plant viral nucleic acid is capable of replication in the host, systemic spread in the host, and transcription or expression of foreign gene(s) in the host to produce the desired product. Such products include therapeutic and other useful polypeptides or proteins such as, but not limited to, enzymes, complex biomolecules, ribozymes, or polypeptide or protein products resulting from anti-sense RNA expression.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 illustrates several vectors prepared in accordance with the present invention and restriction sites. U1 is the native plant viral nucleic acid, 0 is a non-native plant viral nucleic acid, and the hatched area is a non-native plant viral subgenomic

ļ

promoter. The restriction sites are: X-XhoI, N-NsiI, K-KpnI, S-SplI, B-BamHI, No-NcoI, P-PstI. The hatched box (e.g., in TB2) represents the promoter of TMV-O, i.e., 203 bp upstream of the coat protein initiation codon, and the stipled box represents a phage promoter. The open boxes represent open reading frames, and the solid boxes represent cloning vector sequences. The vectors are as follows: A) and B) pTKU1, C) pTMVS3-28, D) pTB2, E) pTBN62 and F) pTBU5.

Figure 2 is an autoradiograph of a Western analysis of the production of α -trichosanthin in N. benthamiana infected in accordance with the present invention. Lane a is molecular size markers, lanes b and c are extracts from yeast engineered to produce α -trichosanthin and lane d is a extract from N. benthamiana.

Figure 3 illustrates the α -trichosanthin expression vector, pBGC152. This plasmid contains the TMV-U1 126-, 183-, and 30-kDa open reading frames (ORFs), the ORSV coat protein gene (Ocp), the SP6 promoter, the α -trichosanthin gene, and part of the pBR322 plasmid. The TAA stop codon in the 30K ORF is underlined and a bar ($\frac{1}{2}$) divides the putative signal peptide from the mature peptide. The TMV-U1 subgenomic promoter located within the minus strand of the 30K ORF controls the expression of α -trichosanthin. The putative transcription start point (tsp) of the subgenomic RNA is indicated with a period(.).

Figure 4 illustrates an electron micrograph of virions from systemically infected leaves of N. benthamiana transfected with in vivo pBGC152 transcripts. The length of the black bar located in

the bottom left corner of the micrograph represents approximately 140 nm.

Figure 5a is a protein analysis of a transfected N. benthamiana plant two weeks after inoculation. a, Western blot analysis. Lane 1: 200 ng of GLQ223; 2: 50 ng of GLQ223; 3: $7\mu g$ of total soluble protein from N. benthamiana infected with pBGC152 transcripts; 4: peak fraction from alkyl superose FPLC chromatography; 5: $7\mu g$ of total soluble protein from noninfected N. benthamiana; 6: $7\mu g$ of total soluble protein from noninfected N. benthamiana and 100 ng of GLQ223.

Figure 5b is a purification profile of recombinant α-trichosanthin. The samples from various stages during purification were analyzed by 12.5% SDS-polyacrylamide gel electrophoresis.

Lane 1: Amersham prestained high-range molecular weight standards; 2: purified GLQ223; 3: total soluble protein from N. benthamiana infected with pBGC152 transcripts; 4: peak fraction from S-sepharose chromatography; 5: peak fraction from alkyl superose FPLC chromatography.

Figure 6 illustrates the inhibition of protein synthesis in a cell-free rabbit reticulocyte translation assay. Dosage required for 50% inhibition (ID₅₀). Purified α-trichosanthin from N. benthamiana infected with BGC 152 transcripts (blackened circles and triangles, repetition 1 and 2), GLQ233 (blackened square), and cycloheximide (open circle) were analyzed in varying concentrations for their ability to inhibit protein synthesis in vitro.

Figure 7 illustrates the construction of the pBGC152 plasmid.

WO 93/03161 PCT/US92/06359

-10-

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to recombinant plant viral nucleic acids and recombinant viruses which are stable for maintenance and transcription or expression of non-native (foreign) nucleic acid sequences and which are capable of systemically transcribing or expressing such foreign sequences in the host plant. More specifically, recombinant plant viral nucleic acids according to the present invention comprise a native plant viral subgenomic promoter, at least one non-native plant viral subgenomic promoter, a plant viral coat protein coding sequence, and optionally, at least one non-native, nucleic acid sequence.

In one embodiment, a plant viral nucleic acid is provided in which the native coat protein coding sequence has been deleted from a viral nucleic acid, a non-native plant viral coat protein coding sequence and a non-native promoter, preferably the subgenomic promoter of the non-native coat protein coding sequence, capable of expression in the plant host, packaging of the recombinant plant viral nucleic acid, and ensuring a systemic infection of the host by the recombinant plant viral nucleic acid, has been inserted. Alternatively, the coat protein gene may be inactivated by insertion of the non-native nucleic acid sequence within it, such that a fusion protein is produced. The recombinant plant viral nucleic acid may contain one or more additional non-native subgenomic promoters. Each non-native subgenomic promoter is capable of transcribing or expressing adjacent genes or nucleic acid sequences in the plant host and incapable of recombination with each other and with native subgenomic promoters. Non-native

(foreign) nucleic acid sequences may be inserted adjacent the native plant viral subgenomic promoter or the native and a non-native plant viral subgenomic promoters if more than one nucleic acid sequence is included. The non-native nucleic acid sequences are transcribed or expressed in the host plant under control of the subgenomic promoter to produce the desired products.

In a second embodiment, a recombinant plant viral nucleic acid is provided as in the first embodiment except that the native coat protein coding sequence is placed adjacent one of the non-native coat protein subgenomic promoters instead of a non-native coat protein coding sequence.

In a third embodiment, a recombinant plant viral nucleic acid is provided in which the native coat protein gene is adjacent its subgenomic promoter and one or more non-native subgenomic promoters have been inserted into the viral nucleic acid. The inserted non-native subgenomic promoters are capable of transcribing or expressing adjacent genes in a plant host and are incapable of recombination with each other and with native subgenomic promoters. Non-native nucleic acid sequences may be inserted adjacent the non-native subgenomic plant viral promoters such that said sequences are transcribed or expressed in the host plant under control of the subgenomic promoters to produce the desired product.

In a fourth embodiment, a recombinant plant viral nucleic acid is provided as in the third embodiment except that the native coat protein coding sequence is replaced by a non-native coat protein coding sequence.

The viral vectors are encapsidated by the coat proteins encoded by the recombinant plant viral

WO 93/03161 PCT/US92/06359

-13-

nucleotide sequence is one capable of encapsidating that viral sequence.

Gene: A discrete nucleic acid sequence
responsible for a discrete cellular product.

<u>Host</u>: A cell, tissue or organism capable of replicating a vector or plant viral nucleic acid and which is capable of being infected by a virus containing the viral vector or plant viral nucleic acid. This term is intended to include procaryotic and eukaryotic cells, organs, tissues or organisms, where appropriate.

Infection: The ability of a virus to transfer its nucleic acid to a host or introduce viral nucleic acid into a host, wherein the viral nucleic acid is replicated, viral proteins are synthesized, and new viral particles assembled. In this context, the terms "transmissible" and "infective" are used interchangeably herein.

Non-Native: Any RNA sequence that promotes production of subgenomic mRNA including, but not limited to, 1) plant viral promoters such as ORSV and vrome mosaic virus, 2) viral promoters from other organisms such as human sindbis viral promoter, and 3) synthetic promoters.

<u>Phenotypic Trait:</u> An observable property resulting from the expression of a gene.

<u>Plant Cell</u>: The structural and physiological unit of plants, consisting of a protoplast and the cell wall.

Plant Organ: A distinct and visibly
differentiated part of a plant, such as root, stem,
leaf or embryo.

<u>Plant Tissue</u>: Any tissue of a plant <u>in planta</u> or in culture. This term is intended to include a whole plant, plant cell, plant organ, protoplast,

cell culture, or any group of plant cells organized into a structural and functional unit.

<u>Production Cell</u>: A cell, tissue or organism capable of replicating a vector or a viral vector, but which is not necessarily a host to the virus. This term is intended to include prokaryotic and eukaryotic cells, organs, tissues or organisms, such as bacteria, yeast, fungus and plant tissue.

<u>Promoter</u>: The 5'-flanking, non-coding sequence adjacent a coding sequence which is involved in the initiation of transcription of the coding sequence.

<u>Protoplast</u>: An isolated plant cell without cell walls, having the potency for regeneration into cell culture or a whole plant.

Recombinant Plant Viral Nucleic Acid: Plant viral nucleic acid which has been modified to contain nonnative nucleic acid sequences.

Recombinant Plant Virus: A plant virus containing the recombinant plant viral nucleic acid.

<u>Subgenomic Promoter</u>: A promoter of a subgenomic mRNA of a viral nucleic acid.

<u>Substantial Sequence Homology</u>: Denotes nucleotide sequences that are substantially functionally equivalent to one another. Nucleotide differences between such sequences having substantial sequence homology will be <u>de minimus</u> in affecting function of the gene products or an RNA coded for by such sequence.

<u>Transcription</u>: Production of an RNA molecule by RNA polymerase as a complementary copy of a DNA sequence.

<u>Vector</u>: A self-replicating DNA molecule which transfers a DNA segment between cells.

<u>Virus</u>: An infectious agent composed of a nucleic acid encapsidated in a protein. A virus may

be a mono-, di-, tri- or multi-partite virus, as described above.

The present invention provides for the infection of a plant host by a recombinant plant virus containing recombinant plant viral nucleic acid or by the recombinant plant viral nucleic acid which contains one or more non-native nucleic acid sequences which are transcribed or expressed in the infected tissues of the plant host. The product of the coding sequences may be recovered from the plant or cause a phenotypic trait, such as male sterility, in the plant.

The present invention has a number of advantages, one of which is that the transformation and regeneration of target organisms is unnecessary. Another advantage is that it is unnecessary to develop vectors which integrate a desired coding sequence in the genome of the target organism. Existing organisms can be altered with a new coding sequence without the need of going through a germ cell. The present invention also gives the option of applying the coding sequence to the desired organism, tissue, organ or cell. Recombinant plant viral nucleic acid is also stable for the foreign coding sequences, and the recombinant plant virus or recombinant plant viral nucleic acid is capable of systemic infection in the plant host.

Chimeric genes and vectors and recombinant plant viral nucleic acids according to this invention are constructed using techniques well known in the art. Suitable techniques have been described in Molecular Cloning (7); Methods in Enzymol. (9); and DNA Cloning (8). Medium compositions have been described in Miller, J.H. (15), as well as the references previously identified. DNA manipulations and nzyme

treatments are carried out in accordance with manufacturers' recommended procedures.

An important feature of the present invention is the preparation of recombinant plant viral nucleic acids (RPVNA) which are capable of replication and systemic spread in a compatible plant host, and which contain one or more non-native subgenomic promoters which are capable of transcribing or expressing adjacent nucleic acid sequences in the plant host. The RPVNA may be further modified to delete all or part of the native coat protein coding sequence and to contain a non-native coat protein coding sequence under control of the native or one of the non-native subgenomic promoters, or put the native coat protein coding sequence under the control of a non-native plant viral subgenomic promoter. The RPVNA have substantial sequence homology to plant viral nucleotide sequences. A partial listing of suitable viruses has been described above. The nucleotide sequence may be an RNA, DNA, cDNA or chemically synthesized RNA or DNA.

of the invention is to modify the nucleotide sequences of the plant viral nucleotide sequence by known conventional techniques such that one or more non-native subgenomic promoters are inserted into the plant viral nucleic acid without destroying the biological function of the plant viral nucleic acid. The subgenomic promoters are capable of transcribing or expressing adjacent nucleic acid sequences in a plant host infected by the recombinant plant viral nucleic acid or recombinant plant virus. The native coat protein coding sequence may be deleted in two embodiments, placed under the control of a non-native subgenomic promoter in a second embodiment, or

retained in a further embodiment. If it is deleted or otherwise inactivated, a non-native coat protein gene is inserted under control of one of the non-native subgenomic promoters, or optionally under control of the native coat protein gene subgenomic promoter. The non-native coat protein is capable of encapsidating the recombinant plant viral nucleic acid to produce a recombinant plant virus. Thus, the recombinant plant viral nucleic acid contains a coat protein coding sequence, which may be native or a nonnative coat protein coding sequence, under control of one of the native or non-native subgenomic promoters. The coat protein is involved in the systemic infection of the plant host.

Some of the viruses which meet this requirement, and are therefore suitable, include viruses from the tobacco mosaic virus group such as Tobacco Mosaic virus (TMV), Cowpea Mosaic virus (CMV), Alfalfa Mosaic virus (AMV), Cucumber Green Mottle Mosaic virus watermelon strain (CGMMV-W) and Oat Mosaic virus (OMV) and viruses from the brome mosaic virus group such as Brome Mosaic virus (MBV), broad bean mottle virus and cowpea chlorotic mottle virus. Additional suitable viruses include Rice Necrosis virus (RNV), and geminiviruses such as tomato golden mosaic virus (TGMV), Cassava latent virus (CLV) and maize streak virus (MSV). Each of these groups of suitable viruses is characterized below.

Tobacco Mosaic Virus Group

Tobacco Mosaic virus (TMV) is a member of the Tobamoviruses. The TMV virion is a tubular filament, and comprises coat protein sub-units arranged in a single right-handed helix with the single-stranded

RNA intercalated between the turns of the helix. TMV infects tobacco as well as other plants. TMV is transmitted mechanically and may remain infective for a year or more in soil or dried leaf tissue.

The TMV virions may be inactivated by subjection to an environment with a pH of less than 3 or greater than 8, or by formaldehyde or iodine. Preparations of TMV may be obtained from plant tissues by $(NH_4)_2SO_4$ precipitation, followed by differential centrifugation.

The TMV single-stranded RNA genome is about 6400 nucleotides long, and is capped at the 5' end but not polyadenylated. The genomic RNA can serve as mRNA for a protein of a molecular weight of about 130,000 (130K) and another produced by read-through of molecular weight about 180,000 (180K). However, it cannot function as a messenger for the synthesis of coat protein. Other genes are expressed during infection by the formation of monocistronic, 3'-coterminal sub-genomic mRNAs, including one (LMC) encoding the 17.5K coat protein and another (I_2) encoding a 30K protein. The 30K protein has been detected in infected protoplasts (16), and it is involved in the cell-to-cell transport of the virus in an infected plant (17). The functions of the two large proteins are unknown.

Several double-stranded RNA molecules, including double-stranded RNAs corresponding to the genomic, I_2 and LMC RNAs, have been detected in plant tissues infected with TMV. These RNA molecules are presumably intermediates in genome replication and/or mRNA synthesis processes which appear to occur by different mechanisms.

TMV assembly apparently occurs in plant cell cytoplasm, although it has been suggested that some

TMV assembly may occur in chloroplasts since transcripts of ctDNA have been detected in purified TMV virions. Initiation of TMV assembly occurs by interaction between ring-shaped aggregates ("discs") of coat protein (each disc consisting of two layers of 17 subunits) and a unique internal nucleation site in the RNA; a hairpin region about 900 nucleotides from the 3' end in the common strain of TMV. Any RNA, including subgenomic RNAs containing this site, may be packaged into virions. The discs apparently assume a helical form on interaction with the RNA, and assembly (elongation) then proceeds in both directions (but much more rapidly in the 3'- to 5'-direction from the nucleation site).

Another member of the Tobamoviruses, the Cucumber green mottle mosaic virus watermelon strain (CGMMV-W) is related to the cucumber virus. Noru, Y. et al. (18). The coat protein of CGMMV-W interacts with RNA of both TMV and CGMMV to assemble viral particles in vitro. Kurisu et al. (19).

Several strains of the tobamovirus group are divided into two subgroups, on the basis of the location of the assembly of origin. Fukuda, M. et al. (20). Subgroup I, which includes the vulgare, OM, and tomato strain, has an origin of assembly about 800-1000 nucleotides from the 3' end of the RNA genome, and outside the coat protein cistron.

Lebeurier, G. et al. (21); and Fukuda, M. et al. (22). Subgroup II, which includes CGMMV-W and cornpea strain (Cc) has an origin of assembly about 300-500 nucleotides from the 3' end of the RNA genome and within the coat-protein cistron. Fukuda, M. et al. (22). The coat protein cistron of CGMMV-W is located at nucleotides 176-661 from the 3' end. The 3' noncoding region is 175 nucleotides long. The

origin of assembly is positioned within the coat protein cistron. Meshi, T. et al. (23).

Brome Mosaic Virus Group

Brome mosaic virus (BV) is a member of a group of tripartite, single-stranded, RNA-containing plant viruses commonly referred to as the bromoviruses. Each member of the bromoviruses infects a narrow range of plants. Mechanical transmission of bromoviruses occurs readily, and some members are transmitted by beetles. In addition to BV, other bromoviruses include broad bean mottle virus and cowpea chlorotic mottle virus.

Typically, a bromovirus virion is icosahedral, with a diameter of about 26 mm, containing a single species of coat protein. The bromovirus genome has three molecules of linear, positive-sense, single-stranded RNA, and the coat protein mRNA is also encapsidated. The RNAs each have a capped 5' end, and a tRNA-like structure (which accepts tyrosine) at the 3' end. Virus assembly occurs in the cytoplasm. The complete nucleotide sequence of BMV has been identified and characterized as described by Alquist et al. (24).

Rice Necrosis Virus

Rice Necrosis virus is a member of the Potato Virus Y Group or Potyviruses. The Rice Necrosis virion is a flexuous filament comprising one type of coat protein (molecular weight about 32,000 to about 36,000) and one molecule of linear positive-sense single-stranded RNA. The Rice Necrosis virus is transmitted by Polymyxa araminis (a eukaryotic

intracellular parasite found in plants, algae and fungi).

Geminiviruses

Geminiviruses are a group of small, single-stranded DNA-containing plant viruses with virions of unique morphology. Each virion consists of a pair of isometric particles (incomplete icosahedra), composed of a single type of protein (with a molecular weight of about 2.7-3.4 x 10⁴). Each geminivirus virion contains one molecule of circular, positive-sense, single-stranded DNA. In some geminiviruses (i.e., Cassava latent virus and bean golden mosaic cirus) the genome appears to be bipartite, containing two single-stranded DNA molecules.

The nucleic acid of any suitable plant virus can be utilized to prepare the recombinant plant viral nucleic acid of the present invention. The nucleotide sequence of the plant virus is modified, using conventional techniques, by the insertion of one or more subgenomic promoters into the plant viral nucleic acid. The subgenomic promoters are capable of functioning in the specific host plant. For example, if the host is tobacco, TMV will be utilized. The inserted subgenomic promoters must be compatible with the TMV nucleic acid and capable of directing transcription or expression of adjacent nucleic acid sequences in tobacco.

The native coat protein gene could also be retained and a non-native nucleic acid sequence inserted within it to create a fusion protein as discussed below. In this example, a non-native coat protein gene is also utilized.

The native or non-native coat protein gene is utilized in the recombinant plant viral nucleic acid. Whichever gene is utilized may be positioned adjacent its natural subgenomic promoter or adjacent one of the other available subgenomic promoters. The non-native coat protein, as is the case for the native coat protein, is capable of encapsidating the recombinant plant viral nucleic acid and providing for systemic spread of the recombinant plant viral nucleic acid in the host plant. The coat protein is selected to provide a systemic infection in the plant host of interest. For example, the TMV-O coat protein provides systemic infection in N.

benthamiana, whereas TMV-U1 coat protein provides systemic infection in N. tabacum.

The recombinant plant viral nucleic acid is prepared by cloning viral nucleic acid in an appropriate production cell. If the viral nucleic acid is DNA, it can be cloned directly into a suitable vector using conventional techniques. technique is to attach an origin of replication to the viral DNA which is compatible with the production If the viral nucleic acid is RNA, a fulllength DNA copy of the viral genome is first prepared by well-known procedures. For example, the viral RNA is transcribed into DNA using reverse transcriptase to produce subgenomic DNA pieces, and a doublestranded DNA made using DNA polymerases. then cloned into appropriate vectors and cloned into a production cell. The DNA pieces are mapped and combined in proper sequence to produce a full-length DNA copy of the viral RNA genome, if necessary. DNA sequences for the subgenomic promoters, with or without a coat protein gene, are then inserted into the nucleic acid at non-essential sites, according to

the particular embodiment of the invention utilized. Non-essential sites are those that do not affect the biological properties of the plant viral nucleic acid. Since the RNA genome is the infective agent, the cDNA is positioned adjacent a suitable promoter so that the RNA is produced in the production cell. The RNA is capped using conventional techniques, if the capped RNA is the infective agent.

A second feature of the present invention is a recombinant plant viral nucleic acid which further comprises one or more non-native nucleic acid sequences capable of being transcribed in the plant The non-native nucleic acid sequence is placed adjacent one or the non-native viral subgenomic promoters and/or the native coat protein gene promoter depending on the particular embodiment used. The non-native nucleic acid is inserted by conventional techniques, or the non-native nucleic acid sequence can be inserted into or adjacent the native coat protein coding sequence such that a fusion protein is produced. The non-native nucleic acid sequence which is transcribed may be transcribed as an RNA which is capable of regulating the expression of a phenotypic trait by an anti-sense mechanism. Alternatively, the non-native nucleic acid sequence in the recombinant plant viral nucleic acid may be transcribed and translated in the plant host, to produce a phenotypic trait. The non-native nucleic acid sequence(s) may also code for the expression of more than one phenotypic trait. The recombinant plant viral nucleic acid containing the non-native nucleic acid sequence is constructed using conventional techniques such that non-native nucleic acid sequence(s) are in proper orientation to whichever viral subgenomic promoter is utilized.

WO 93/03161 PCT/US92/06359

Useful phenotypic traits in plant cells include, but are not limited to, improved tolerance to herbicides, improved tolerance to extremes of heat or cold, drought, salinity or osmotic stress; improved resistance to pests (insects, nematodes or arachnids) or diseases (fungal, bacterial or viral) production of enzymes or secondary metabolites; male or female sterility; dwarfness; early maturity; improved yield, vigor, heterosis, nutritional qualities, flavor or processing properties, and the like. Other examples include the production of important proteins or other products for commercial use, such as lipase, melanin, pigments, antibodies, hormones, pharmaceuticals, antibiotics and the like. Another useful phenotypic trait is the production of degradative or inhibitory enzymes, such as are utilized to prevent or inhibit root development in malting barley. The phenotypic trait may also be a secondary metabolite whose production is desired in a bioreactor.

A double-stranded DNA of the recombinant plant viral nucleic acid or a complementary copy of the recombinant plant viral nucleic acid is cloned into a production cell. If the viral nucleic acid is an RNA molecule, the nucleic acid (cDNA) is first attached to a promoter which is compatible with the production cell. The RPVNA can then be cloned into any suitable vector which is compatible with the production cell. In this manner, only RNA copies of the chimeric nucleotide sequence are produced in the production For example, if the production cell is E. coli, the lac promoter can be utilized. production cell is a plant cell, the CaMV promoter can be used. The production cell can be a eukaryotic cell such as yeast, plant or animal, if viral RNA must be capped for biological activity.

Alternatively, the RPVNA is inserted in a vector adjacent a promoter which is compatible with the production cell. If the viral nucleic acid is a DNA molecule, it can be cloned directly into a production cell by attaching it to an origin of replication which is compatible with the production cell. In this manner, DNA copies of the chimeric nucleotide sequence are produced in the production cell.

A promoter is a DNA sequence that directs RNA polymerase to bind to DNA and to initiate RNA synthesis. There are strong promoters and weak promoters. Among the strong promoters are lacuv5, trp, tac, trp-lacuv5, λ pl, ompF, and bla. A useful promoter for expressing foreign genes in <u>E. coli</u> is one which is both strong and regulated. The λ pl promoter of bacteriophage λ is a strong, well-regulated promoter. Hedgpeth, J.M. et al. (25); Bernard, H.M. et al. (26); Remaut, E.P. et al. (27).

A gene encoding a temperature-sensitive λ repressor such as λ cIts 857 may be included in the cloning vector. Bernard et al. (26). At low temperature (31°C), the p_1 promoter is maintained in a repressed state by the cI-gene product. Raising the temperature destroys the activity of the repressor. The p_1 promoter then directs the synthesis of large quantities of mRNA. In this way, <u>E. coli</u> production cells may grow to the desired concentration before producing the products encoded within the vectors. Similarly, a temperature-sensitive promoter may be activated at the desired time by adjusting the temperature of the culture.

It may be advantageous to assemble a plasmid that can conditionally attain very high copy numbers. For example, the pAS2 plasmid containing a <u>lac</u> or <u>tac</u> promoter will achieve very high copy numbers at 42°C.

The <u>lac</u> repressor, present in the pAS2 plasmid, is then inactivated by isopropyl- β -D-thiogalactoside to allow synthesis of mRNA.

A further alternative when creating the RPVNA is to prepare more than one nucleic acid (i.e., to prepare the nucleic acids necessary for a multipartite viral vector construct). In this case, each nucleic acid would require its own origin of assembly. Each nucleic acid could be prepared to contain a subgenomic promoter and a non-native nucleic acid.

Alternatively, the insertion of a non-native nucleic acid into the nucleic acid of a monopartite virus may result in the creation of two nucleic acids (i.e., the nucleic acid necessary for the creation of a bipartite viral vector). This would be advantageous when it is desirable to keep the replication and transcription or expression of the non-native nucleic acid separate from the replication and translation of some of the coding sequences of the native nucleic acid. Each nucleic acid would have to have its own origin of assembly.

A third feature of the present invention is a virus or viral particle. The virus comprises a RPVNA as described above which has been encapsidated. The resulting product is then capable of infecting an appropriate plant host. The RPVNA sequence is transcribed and/or translated within the plant host to produce the desired product.

In one embodiment of the present invention, the recombinant plant viral nucleic acid is encapsidated by a heterologous capsid. Most commonly, this embodiment will make use of a rod-shaped capsid because of its ability to encapsidate a longer RPVNA than the more geometrically constrained icosahedral

capsid or spherical capsid. The use of a rod-shaped capsid permits incorporation of a larger non-native nucleic acid to form the RPVNA. Such a rod-shaped capsid is most advantageous when more than one non-native nucleic acid is present in the RPVNA.

Another feature of the invention is a vector containing the RPVNA as described above. The RPVNA is adjacent a nucleotide sequence selected from the group consisting of a production cell promoter or an origin of replication compatible with the production cell. The vector is utilized to transform a production cell which will then produce the RPVNA in quantity. The production cell may be any cell which is compatible with the vector, and may be prokaryotic or eukaryotic. However, if the viral RNA (RPVNA) must be capped in order to be active, the production cell must be capable of capping the viral RNA, such as a eukaryotic production cell.

A further feature of the present invention is a host which has been infected by the recombinant plant virus or viral nucleic acid. After introduction into a host, the host contains the RPVNA which is capable of self-replication, encapsidation and systemic spread. The host can be infected with the recombinant plant virus by conventional techniques. Suitable techniques include, but are not limited to, leaf abrasion, abrasion in solution, high velocity water spray and other injury of a host as well as imbibing host seeds with water containing the recombinant plant virus. More specifically, suitable techniques include:

(a) <u>Hand Inoculations</u>. Hand inoculations of the encapsidated vector are performed using a neutral pH, low molarity phosphate buffer, with the addition of celite or carborundum (usually about 1%) One to four

drops of the preparation is put onto the upper surface of a leaf and gently rubbed.

- (b) <u>Mechanized Inoculations of Plant Beds</u>.

 Plant bed inoculations are performed by spraying (CO₂-propelled) the vector solution into a tractordriven mower while cutting the leaves.

 Alternatively, the plant bed is mowed and the vector solution sprayed immediately onto the cut leaves.
- (c) <u>High Pressure Spray of Single Leaves</u>. Single plant inoculations can also be performed by spraying the leaves with a narrow, directed spray (50 psi, 6-12 inches from the leaf) containing approximately 1% carborundum in the buffered vector solution.

An alternative method for introducing a RPVNA into a plant host is a technique known as agroinfection or Agrobacterium-mediated transformation (sometimes called Agro-infection) as described by Grimsley, N. et al. (28). This technique makes use of a common feature of Agrobacterium which colonizes plants by transferring a portion of their DNA (the T-DNA) into a host cell, where it becomes integrated into nuclear DNA. T-DNA is defined by border sequences which are 25 base pairs long, and any DNA between these border sequences is transferred to the plant cells as well. The insertion of a RPVNA between the T-DNA border sequences results in transfer of the RPVNA to the plant cells, where the RPVNA is replicated, and then spreads systemically through the plant. Agroinfection has been accomplished with potato spindle tuber viroid (PSTV) (Gardner, R.C. et al. (29)); CaV (Grimsley, N. et al. (30)); MSV (Grimsley, N. et al. (28), supra) and Lazarowitz, S.C. (31)), digitaria streak virus (D nson, J. et al. (32)), wheat dwarf

virus (Hayes, R.J. et al. (33)) and tomato golden mosaic virus (TGMV) (Elmer, J.S. et al. (34) and Gardiner, W.E. et al. (35)). Therefore, agroinfection of a susceptible plant could be accomplished with a virion containing a RPVNA based on the nucleotide sequence of any of the above viruses.

A still further feature of the invention is a process for the production of a specified polypeptide or protein product such as, but not limited to, enzymes, complex biomolecules, a ribozyme, or polypeptide or protein products resulting from antisense RNA. Such products include, but not limited to: IL-1, IL-2, IL-3, ... IL-12, etc.; EPO; CSF including G-CSF, GM-CSF, hPG-CSF, M-CSF, etc; Factor VIII; Factor IX; tPA; hGH; receptors and receptor antagonists; antibodies; neuro-polypeptides; melanin; insulin; vaccines and the like. The non-native nucleic acid of the RPVNA comprises the transcribable sequence which leads to the production of the desired product. This process involves the infection of the appropriate plant host with a recombinant virus or recombinant plant viral nucleic acid such as those described above, the growth of the infected host to produce the desired product, and the isolation of the desired product, if necessary. The growth of the infected host is in accordance with conventional techniques, as is the isolation of the resultant product.

For example, a coding sequence for a protein such as neomycin phosphotransferase (NPTII) α -trichosanthin, rice α -amylase, human α -hemoglobin or human β -hemoglobin, is inserted adjacent the promoter of the TMV coat protein coding sequence, which has been deleted. In another example, a

tyrosinase coding sequence such as isolated from Streptomyces antibioticus is inserted adjacent the same promoter of TMV, oat mosaic virus (OMV) or rice necrosis virus (RNV). Recombinant virus can be prepared as described above, using the resulting recombinant plant viral nucleic acid. Tobacco or germinating barley is infected with the recombinant virus or recombinant plant viral nucleic acid. The viral nucleic acid self-replicates in the plant tissue to produce the enzymes amylase or tyrosinase. The activity of this tyrosinase leads to the production of melanin. See, for example, Huber, M. et al. (36).

In a further example, a cyclodextrin glucanotransferase coding sequence, such as isolated from Bacillus sp. No. 17-1 (see U.S. Patent 4,135,977) is inserted adjacent the promoter of the viral coat protein of a nucleotide sequence derived from OMV, RNV, PVY or PVX in which the coat protein coding sequence has been removed, and which then contains a non-native promoter and coat protein gene. Corn or potato is infected with the appropriate recombinant virus or recombinant plant viral nucleic acid to produce the enzyme cyclodextrin glucotransferase. The activity of this enzyme leads to the production of cyclodextrin, which is useful as a flavorant or for drug delivery.

In some plants, the production of anti-sense RNA as a product can be useful to prevent the expression of certain phenotypic traits. Particularly, some plants produce substances which are abused as drugs (e. g., cocaine is derived from the coca plant, and tetrahydrocannabinol (THC) is the active substance of abuse derived from cannabis or marijuana plants). An anti-sense RNA complementary to the plant RNA

necessary for the production of an abusable substance would prevent the production of the substance. This could prove to be an effective tool in reducing the supply of illegal drugs.

A still further feature of the invention is a process for the production of an enzyme suitable for the stereospecific catalysis of an organic compound. The non-native nucleic acid comprises the transcribable sequence which leads to the production of the desired product. This process involves the infection of the appropriate host with a recombinant virus or recombinant plant viral nucleic acid such as those described above, the growth of the infected host to produce the desired product and the isolation of the desired product. The growth of the infected host is in accordance with conventional techniques, as is the isolation of the resultant product. The stereospecific enzyme is then utilized to catalyze the desired reaction. One use of stereospecific enzymes is in the separation of racemate mixtures.

In one example, a suitable esterase or lipase coding sequence such as isolated from an appropriate microorganism is inserted adjacent the promoter of the viral coat protein of a nucleotide sequence derived from TMV, oat mosaic virus (OMV) or rice necrosis virus (RNV) in which the coat protein coding sequence has been removed and which then contains a non-native promoter and coat protein gene. Tobacco or germinating barley is infected with the recombinant virus or recombinant plant viral nucleic acid to produce the esterase or lipase enzyme. This enzyme is isolated and used in the stereospecific preparation of a compound such as naproxen, as described in EP-A 0233656 or EP-A 0227078.

An esterase coding sequence is isolated from the appropriate microorganism, such as Bacillus subtilis, Bacillus licheniformis (a sample of this species is deposited with the American Type Culture Collection, Rockville, Maryland (ATCC) under Accession No. 11945), <u>Pseudomonas fluorescens</u>, <u>Pseudomonas putida</u> (a sample of this species is deposited with the Institute for Fermentation (IFO), Osaka, Japan, under Accession No. 12996), Pseudomonas riboflavina (a sample of this species is deposited with IFO under Accession No. 13584), Pseudomonas ovalis (a sample of this species is deposited with the Institute of Applied Microbiology (SAM), University of Tokyo, Japan, under Accession No. 1049), Pseudomonas aeruainosa (IFO 13130), Mucor angulimacrosporus (SAM 6149), Arthrobacter paraffineus (ATCC 21218), Strain is III-25 (CBS 666.86), Strain LK 3-4 (CBS 667.86), Strain Sp 4 (CBS 668.86), Strain Thai III 18-1 (CBS 669.86), and Strain Thai VI 12 (CBS 670. 86). Advantageously, cultures of species <u>Bacillus</u> <u>subtilis</u> include cultures of species <u>Bacillus</u> <u>species</u> <u>Thai</u> 1-8 (CBS 679.85), species Bacillus species In IV-8 (CBS 680.85), species <u>Bacillus species Nap 10-M</u> (CBS 805.85), species Bacillus species Sp 111-4 (CBS 806.85), Bacillus subtilis 1-85 (Yuki, S. et al., Japan J. Gen. 42:251 (1967)), Bacillus subtilis 1-85/pNAPT-7 (CBS 673.86), Bacillus subtilis 1A-40/pNAPT-8 (CBS 674.86), and Bacillus subtilis 1A-40/pNAPT-7 (CBS 675. 86). Advantageously, cultures of <u>Pseudomonas fluorescens</u> include a culture of species Pseudomonas species Kpr 1-6 (CBS 807.85), and Pseudomonas fluorescens species (IFO 3081).

A lipase coding sequence is isolated from the appropriate microorganism such as the genera <u>Candida</u>, <u>Rhizopus</u>, <u>Mucor</u>, <u>Aspergilus</u>, <u>Penicillium</u>,

<u>Pseudomonas</u>, <u>Chromobacterium</u>, and <u>Geotrichium</u>. Particularly preferred is the lipase of <u>Candida</u> <u>cylindracea</u> (Qu-Ming et al., Tetrahedron Letts. 27, 7 (1986)).

A fusion protein can be formed by incorporation of the non-native nucleic acid into a structural gene of the viral nucleic acid, e.g., the coat protein gene. The regulation sites on the viral structural gene remain functional. Thus, protein synthesis can occur in the usual way, from the starting codon for methionine to the stop codon on the foreign gene, to produce the fusion protein. The fusion protein contains at the amino terminal end a part or all of the viral structural protein, and contains at the carboxy terminal end the desired material, e.g., a stereospecific enzyme. For its subsequent use, the stereospecific enzyme must first be processed by a specific cleavage from this fusion protein and then further purified. A reaction with cyanogen bromide leads to a cleavage of the peptide sequence at the carboxy end of methionine residues (5.0. Needleman, "Protein Sequence Determination", Springer Publishers, 1970, N.Y.). Accordingly, it is necessary for this purpose that the second sequence contain an additional codon for methionine, whereby a methionine residue is disposed between the N-terminal native protein sequence and the C-terminal foreign protein of the fusion protein. However, this method fails if other methionine residues are present in the desired protein. Additionally, the cleavage with cyanogen bromide has the disadvantage of evoking secondary reactions at various other amino acids.

Alternatively, an oligonucleotide segment, referred to as a "linker," may be placed between the second sequence and the viral sequence. The linker

codes for an amino acid sequence of the extended specific cleavage site of a proteolytic enzyme as well as a specific cleavage site (see, for example, U.S. Patent Nos. 4,769,326 and 4,543,329). The use of linkers in the fusion protein at the amino terminal end of the non-native protein avoids the secondary reactions inherent in cyanogen bromide cleavage by a selective enzymatic hydrolysis. An example of such a linker is a tetrapeptide of the general formula Pro-Xaa-Gly-Pro(SEQ ID NO: 1) (aminoterminal end of non-native protein), wherein Xaa is any desired amino acid. The overall cleavage is effected by first selectively cleaving the xaa-Gly bond with a collagenase (E.C. 3.4.24.3., Clostridiopeptidase A) then removing the glycine residue with an aminoacyl-proline aminopeptidase (aminopeptidase-P, E.C. 3.4.11.9.) and removing the proline residue with a proline amino peptidase (E.C. 3.4.11.5). In the alternative, the aminopeptidase enzyme can be replaced by postproline dipeptidylaminopeptidase. Other linkers and appropriate enzymes are set forth in U.S. Patent No. 4,769,326.

A still further feature of the invention is a process for the induction of male sterility in plant. Male sterility can be induced by several mechanisms, including, but not limited to, an anti-sense RNA mechanism, a ribozyme mechanism, or a protein mechanism which may induce male sterility or self-incompatibility or interfere with normal gametophytic development. The second nucleotide sequence of the chimeric nucleotide sequence comprises the transcribable sequence which leads to the induction of male sterility. This process involves the infection of the appropriate plant with a virus, such

as those described above, and the growth of the infected plant to produce the desired male sterility. The growth of the infected plant is in accordance with conventional techniques.

Male sterility can be induced in plants by many mechanisms including, but not limited to (a) absence of pollen formation, (b) formation of infertile and/or non-functional pollen, (c) selfincompatibility, (d) inhibition of selfcompatibility, (e) perturbation of mitochondrial function(s), (f) alteration of the production of a hormone or other biomolecule to interfere with normal gametophytic development, or (g) inhibition of a developmental gene necessary for normal male gametophytic tissue. These mechanisms may be accomplished by using anti-sense RNA, ribozymes, genes or protein products. The recombinant plant viral nucleic acids of the present invention contain one or more nucleotide sequences which function to induce male sterility in plants. To accomplish this function, the recombinant plant viral nucleic acids may contain a nucleotide sequence, a single gene or a series of genes.

Male sterility traits could be formed by isolating a nuclear-encoded male sterility gene.

Many of these genes are known to be single genes.

For example, Tanksley et al. (37) placed ms-10 in CIS with a rare allele of the tightly linked enzyme-coding gene Prx-2. The Prx-2 allele is codominant, allowing selection for heterozygous plants carrying the recessive ms-10 allele in backcross populations and eliminating the need for progeny testing during transfer of the gene into parents for hybrid production. A male-sterile anthocyaninless plant (ms-10 aa/ms-10aa) was crossed to a heterozygous,

fertile plant in which a rare peroxidase allele was in cis with the recessive male-sterile allele (ms-10 Prx-2'/+Prx-2+). Male sterile plants were selected from the progeny (ms-10 Prx-2'/ms-10aa). Once the male-sterile gene has been transferred into a prospective parental line, sterile plants can be selected at the seedling stage either from backcross or F₂ seed lots.

In pearl millet, recessive male sterile genes were found in vg 272 and IP 482. Male sterility in pearl millet line Vg 272 and in IP 482 is essentially controlled by a single recessive gene. Male sterility in Vg 272 is due to a recessive gene, ms, which has no effect on meiosis in pollen mother cells, but acts after separation of microspores from tetrads but before onset of the first mitotic division.

Dewey et al. (39) isolated and characterized a 3547 bp fragment from male sterile (cms-T) maize mitochondria, designated TURF 243. TURF 243 contains two long open reading frames that could encode polypeptides of 12,961 Mr and 24,675 Mr. TURF 243 transcripts appeared to be uniquely altered in cms-T plants restored to fertility by the nuclear restorer genes Rf1 and Rf2. A fragment of maize mtDNA from T cytoplasm was characterized by nucleotide sequence analysis. To obtain isolation of nucleic acids, mitochondrial RNA (mtRNA), and mtDNA were prepared from six- to seven-day-old dark grown seedlings of Zea Mays L. by conventional techniques.

Another means by which male sterile traits could be formed is by the isolation of a male sterility gene from a virus. There are several viruses or virus-like particles that induce male sterility in plants. Recent work suggests that viroid-like agents

in male sterile beets may occur. (40). Cytoplasmic male sterility may be conditioned by a discrete particle such as a plasmid or an inclusion. Viruses are not seed transmitted with the regularity of cytosterile systems. Viroids can be transmitted through pollen. Transfer of a factor of some kind across a graft union has been demonstrated in petunia, beet, sunflower, and alfalfa. There is no direct effect on the fertility of the scion, but selfs or crosses by a maintainer on the grafted scion produced male sterile plants in the next generation. Cms beets grown at 36°C for 6 weeks, then at 25°C, produced fertile plants from new shoots possibly due to elimination of "cytoplasmic spherical bodies", but progenies from the plants reverted to sterility after three generations at normal growing conditions. Cytoplasmic male sterility in the broad bean plant (Vicia fabal) was found to be caused by the presence of virus or virus-like particles. Possibly a case similar to a cms-system occurs in garlic. Pollen degeneration typical of sporophytic cms plants was found, but electron microscope studies showed richettsia-like inclusions in the anthers, which could be eliminated with antibiotics, causing the pollen to become fertile (41).

Male sterile traits could be formed by a third method of introducing an altered protein, using a transit peptide sequence so that it will be transported into the mitochondria, and perturbing the mitochondrial functions. This protein could work to overwhelm normal mitochondrial function or reduce a metabolite required in a vital pathway. It is widely believed that slight perturbations in the mitochondria will lead to male sterility. Remy et al. (42) conducted a two dimensional analysis of

untimely degeneration as a result of conversion from glandular to periplasmodial type.

A sixth method for inducing male sterility in plants is by isolating a self-incompatibility gene and using the gene in the vector of the present invention. Self-incompatibility (S) gene systems that encourage out-breeding are present in more than 50% of the angiosperm plant families (44). Multiple S gene systems are known in some species. In several systems, abundant style glycoproteins (S glycoproteins) have been identified. glycoproteins are polymorphic and can be correlated with identified S alleles. S genes, corresponding to the style glycoproteins of N. alaba and B. oleraceae have been cloned and sequenced. Amino acid substitutions and deletions/insertions, although present throughout the sequences, tend to be clustered in regions of hypervariability that are likely to encode allelic specificity.

A seventh method for inducing male sterility in plants is by blocking self incompatibility, by the engineering of a protein that will bind and inactivate the compatibility site or by turning off self-compatibility, by the engineering of an antisense RNA that will bind with the mRNA to a self-compatibility protein.

Specific effects resulting in male sterility can range from the early stages of sporogenous cell formation right through to a condition in which anthers containing viable pollen do not dehisce. Some or all of the developmental stages within this range may be affected. Some of the more obvious specific effects include, the following examples:

1) Meiosis is disrupted, leading to degeneration of the pollen mother cells or early microspores in

which case pollen aborts and anther development is arrested at an early stage.

- 2) Exine formation is disrupted and microspores are thin-walled, perhaps distorted in shape, and nonviable. Anthers are generally more developed than the exines, but still not normal.
- 3) Microspore vacuole abnormalities, decreased starch deposition and tapetum persistence are evident. Pollen is nonviable and anthers are still not normal.
- 4) Pollen is present and viable, and anthers appear normal but either do not dehisce or show much delayed dehiscence.
- 5) Self incompatibility mechanisms disrupt or prevent enzymatic digestion of the style by the pollen grain.

Male sterility in plants may be induced by the mechanisms listed above at any stage prior to pollen shed. The male sterility mechanism selected may be applied to plants in the field (or in the greenhouse) at any time after seedling emergence and before pollen shed. The exact time of application will depend on the male sterility mechanism used and the optimum effectiveness in producing male sterile plants.

EXAMPLES

In the following examples, enzyme reactions were conducted in accordance with manufacturers recommended procedures, unless otherwise indicated. Standard techniques, such as those described in Molecular Cloning (7), Meth.in Enzymol. (9) and DNA Cloning (8), were utilized for vector constructions and transformation unless otherwise specified.

COMPARATIVE EXAMPLES

The following comparative examples demonstrate either the instability of prior art recombinant viral nucleic acid during systemic infection of host plants or the inability to systemically infect plants and to efficiently produce the product of the inserted nonnative gene.

Comparative Example 1

Recombinant plant viral nucleic acid was prepared by inserting the chloramphenical acetyltransferase (CAT) gene which had been fused behind a TMV subgenomic RNA promoter between the 30K and coat protein genes of TMV. pTMV-CAT-CP was prepared as described by Dawson, W.O. et al. (11). Briefly, pTMV-CAT-CP was constructed by cutting pTMV204, a full-genomic cDNA clone of TMV strain U1 (4) with NcoI (nt. 5460), blunting with Klenow fragment of DNA polymerase I, adding PstI linkers (CCTGCACG from Boehringer-Mannheim Biochemicals), excising with PstI and NsiI (nt. 6207), and ligating this 747-bp fragment into the NsiI site (nt. 6207) of pTMV-S3-CAT-28, a modified TMV with the CAT ORF substituted for the coat protein ORF (45). TMV nucleotide numbering is that of Goelet et al. (46). Correct ligation and orientation of each construct were checked by restriction mapping and sequencing.

Inoculations. In vitro transcription of plasmid DNA constructs and inoculation procedures were as described previously (3). Virus was propagated systemically in Xanthi tobacco (Nicotiana tabacum L.) and Nicotiana sylvestris: Xanthi-nc tobacco was used as a local lesion host. Plants were grown in a greenhouse prior to inoculations and then subsequently maintained in plant growth chambers at

25° with a 16-hour photoperiod of approximately 2000 lx.

<u>CAT Assays</u>. Amounts of CAT activity were assayed essentially by the procedures described (47), 200 mg of leaf tissue were macerated in assay buffer followed by addition of 0.5 mM acetyl CoA and 0.1 μ Ci [\frac{14}{C}]-chloramphenicol, incubation for 45 minutes at 37°, extraction and resolution by thin-layer chromatography, and finally autoradiography.

RNA Analysis. Four days after inoculation, total RNA from infected leaves was extracted as described (47a). For blot hybridization analysis, RNA was electrophoresed in 1.2% agarose gels, transferred to nitrocellulose, and hybridized with nick-translated cDNA of TMV (nts. 5080-6395) in pUC119 or pCM1 (Pharmacia) which contains the CAT ORF. Total RNA from infected leaves also was analyzed by RNase protection assays for wild-type sequences essentially as described in Ausubel et al. (48). The 3' half (BamHI:nt. 3332-PstI:nt. 6401) of pTMV204 was cloned into pT7/T3-19 (from BRL). After EcoRI digestion (nt. 4254), 32P-labeled transcripts complementary to the 3' viral sequencs were produced . with T7 RNA polymerase. An excess amount of the probe was hybridized to RNA samples, treated with 40 μg/ml RNase A (Sigma) and 300 U RNase T1 (BRL) extracted, denatured with DMSO and glyoxal, and electrophoresed in 1.2% agarose gels which were subsequently dried and exposed to Kodak X-ray film.

Construction of cDNA Clones of ProgenY Virus.

RNA was extracted from purified virions and cDNA was prepared as previously described (4) Double-stranded cDNA was digested with BamHI (nt. 3332) and SacI (nt. 6142) and cloned into BamHI- and SacI-digested pUC19.

Nucleotide sequencing of DNA was by the dideoxynucleotide chain terminating procedure (49).

Results. In vitro transcripts of pTMC-CAT-CP, which had the CAT cartridge inserted upstream of the coat protein gene, resulted in CAT-CP, a hybrid virus 7452 nucleotides in length and a gene order of 126K, 183K, 30K, CAT and coat protein. In vitro transcripts were used to inoculate leaves of N. tabacum L. varieties Xanthi and Xanthi-nc and N. sylvestris. Results were compared to those from plants infected with wild-type virus, TMV 204, or the free-RNA virus, S30CAT-28, that expresses CAT as a replacement for coat protein (45) CAT-CP replicated effectively and moved from cell to cell in inoculated leaves similarly to TMV 204. Necrotic lesions developed on Xanthi-nc tobacco at approximately the same time and were of the same size as those caused by TMV 204 and S3-CAT-2B. CAT-CP induced no symptoms in inoculated leaves of the systemic hosts, Xanthi tobacco and N. sylvestris, but produced mosaic symptoms in developing leaves similar to those produced by TMV 204. The concentration of virions in cells infected with CAT-CP, estimated by yields obtained after virion purification and by transmission electron microscopy of thin sections of inoculated leaves, appeared to be approximately equal to that from a TMV 204 infection.

CAT-CP is 7452 nucleotides long, compared to 6395 nucleotides for TMV 204, whih would result in CAT-CP virions 350 nm in length, compared to the 300 nm virions of wild-type TMV. Virus was purified from inoculated leaves of CAT-CP-infected plants and analyzed by transmission electron microscopy. Most of the virions from the CAT-CP infections were 350 nm in length. One problem in assessing the length of

virions of TMV UI viewed by electron microscopy is that preparations normally contain fragmented and end-to-end aggregated virions in addition to individual genomic-length virions. To determine the proportion of 350- to 300-nm virions, distinct, individual virions of each size were counted. The ratio of 350/300 nm virions in leaves inoculated with CAT-CP was 191:21, compared to 12:253 from the wild-type infection. The 350-nm virions in wild-type TMV infection probably resulted from the end-to-end aggregation of fragmented virions, since TMV UI has a propensity to aggregate end-to-end and all length virions can be found. These data suggest that the extra gene of CAT-CP was maintained and encapsidated in these inoculated leaves.

CAT activity was detected in leaves inoculated with CAT-CP using in vitro RNA transcripts or the subsequent first or second passage local lesions. From more than one hundred samples assayed, a range of variation was found among different positive samples. Similar levels of CAT were found in CAT-CP-infected leaves as those infected with the coat protein-less mutant, S3-CAT-2 B. Only background amounts were detected in TMV 204-infected or healthy leaves.

The host range of CAT-CP was compared to that of wild-type TMV by inoculating a series of hosts known to support replication of TMV and by screening for CAT activity. CAT activity was detected in inoculated leaves of Zinnia eleaans Jacq., Lunaria annua L., Beta vulaaris L., Calendula officinalis L., and Spinacia oleracea L., which represent three plant families in addition to the Solanaceae. This indicated that this alteration of the TMV genome did not appear to alter the host range.

In rder to determine whether CAT-CP produced an additional subgenomic RNA as a result of the inserted sequences, total RNA from infected leaves was extracted and compared to that of wild-type TMV by blot hybridization analysis, using a TMV or a CAT DNA Xanthi tobacco leaves infected with CAT-CP previously passaged twice in xanthi-nc tobacco were chosen because they contained a population of CAT-CP and progeny virus with deletions to be compared to wild-type TMV. Two distinct genomic RNAs were detected. The largest hybridized to both TMV and CAT probes, whereas the smaller genomic RNA hybridized only to the TMV probe and comigrated with wild-type Tv genomic RNA. Three distinct, small RNAs were found in RNA from CAT-CP-infected leaves, compared to two from TMV 204-infected leaves. The smaller RNAs that comigrated with the subgenomic messages for the coat and 30K proteins of wild-type TMV hybridized only to the Tv-specific probe. A larger subgenomic RNA from CAT-CP-infected leaves hybridized to both the CAT and TMV probes. Assuming that as for the subgenomic mRNAs of wild-type TMV, this larger subgenomic RNA is 3' coterminal with the genomic RNA (50), these results are consistent with the extra CAT-CP mRNA predicted for expression of CAT. The putative CAT-CP subgenomic RNA for 30K protein, containing the 30K, CAT, and coat protein ORFs was not observed, possibly because bands in the region between 2.4 and 4.4 kb were obscured by viral RNAs adhering during electrophoresis to host rRNAs and were difficult to resolve (50, 51).

The amounts of CAT activity in upper, systemically infected leaves were variable and much lower than in inoculated leaves, and in many cases none was detected. Hybridizations with Tv and CAT

probes demonstrated that the proportion of virusretaining CAT sequences was quickly reduced to
undetectable levels. The transition from CAT-CP to
a population of virus with the inserted CAT ORF
deleted occurred during systermic invasion of the
plant and sometimes in inoculated leaves. In
contrast, CAT sequences and CAT activity often were
detected in leaves inoculated with virus that had
been passaged through single lesions three or four
times.

CAT-CP virions were examined from systemically infected Xanthi tobacco leaves approximately 30 days after inoculation. Quantification of virions from the uppermost leaves of the plants infected with CAT-CP produced a ratio of 350-/300-nm virions of 78:716. This was compared to a ratio of 191:21 in inoculated leaves, indicating that the major component of the population shifted to 300-nm virions during systemic infection. The deleted progeny virus recovered after continued replication of CAT-CP was identical in host range and symptomatology to wild-type TMV.

cDNA of the region that encompassed the CAT insertion (nts. 3332-6142) was cloned from the progeny CAT-CP virion RNA from systemically infected Kanthi leaves to sample the virus population. Characterization of nine cDNA clones by size and restriction mapping indicated that eight were identical with wild-type TMV.

One cDNA clone appeared to be the size predicted for the CAT-CP construct, but the restriction map varied from that predicted for CAT-CP. Five clones that were evaluated by size and restriction analysis as wild-type were sequenced through the region of the CAT insertion and also through a portion of the coat

protein gene, and found to be identical to the parental wild-type virus. This suggested the inserted sequences could be excised, giving rise to wild-type TMV.

To corroborate this possible excision, samples of the total leaf RNA used in the blot hybridization analysis were analyzed by RNase protection assays using T7-produced minus-strand RNA complementary to in inoculated leaves. In contrast, CAT sequences and CAT activity often were detected in leaves inoculated with virus that had been passaged through single lesions three or four times.

CAT-CP virions were examined from systemically infected Xanthi tobacco leaves approximately 30 days after inoculation. Quantification of virions from the uppermost leaves of the plants infected with CAT-CP produced a ratio of 350- /300-nm virions of 78:716. This was compared to a ratio of 191:21 in inoculated leaves, indicating that the major component of the population shifted to 300-nm virions during systemic infection. The deleted progeny virus recovered after continued replication of CAT-CP was identical in host range and symptomatology to wild-type TMV.

cDNA of the region that encompassed the CAT insertion (nts. 3332-6142) was cloned from the progeny CAT-CP virion RNA from systemically infected Xanthi leaves to sample the virus population. Characterization of nine cDNA clones by size and restriction mapping indicated that eight were identical with wild-type TMV.

One cDNA clone appeared to be the size predicted for the CAT-CP construct, but the restriction map varied from that predicted for CAT-CP. Five clones that were valuated by size and restriction analysis as wild-type were sequenced through the region of the CAT insertion and also through a portion of the coat protein gene, and found to be identical to the parental wild-type virus. This suggested the inserted sequences could be excised, giving rise to wild-type TMV.

To corroborate this possible excision, samples of the total leaf RNA used in the blot hybridization analysis were analyzed by RNase protection assays using T7-produced minus-strand RNA complementary to nucleotides 4254-6395 of wild-type TMV. The presence of wild-type sequences in this region would result in a protected RNA of 2140 nucleotides. A band this size from the CAT-CP RNAs comigrated with a similar band produced suing wild-type RNA to protect the probe. These data confirmed that the inserted sequences of CAT-CP could be precisely deleted. Taking into consideration the presence of repeated sequences in CAT-CP RNA that allow the bulge loop in the hybrid between CAT-CP and the wild-type TMV probe RNA to occur over a range of positions within the repeats, the RNase protection of wild-type probe by CAT-CP RNA should produce sets of bands that would fall within two nucleotide size ranges, 683-935 and 1202-1458. The other two major bands seen are of these sizes, corroborating the presence of CAT-CP RNA in these samples.

The loss of the inserted sequences of CAT-CP appeared to be due to two sequential processes. First was the loss of inserted sequences in individual molecules, as shown by the sequence analysis of cDNA clones of progeny virus. Since the deletion occurred between repeated sequences, it is possible that this occurred by homologous recombination as described for other plus-sense RNA

viruses (52-54) The second process resulted in a selected shift in the virus population. The RNase protection assays, in which the virus population was sampled, demonstrated that both CAT-CP and wild-type virus could be components of the population in inoculated leaves. The lack of CAT-CP in systemically infected leaves was probably due to a shift in the virus population, possibly because the original hybrid could not effectively compete with the deleted progeny wild-type virus in terms of replication and systemic movement.

Comparative Example 2

A recombinant plant viral nucleic acid was prepared by inserting the CAT gene which had been fused behind a TMV subgenomic RNA promoter between the coat protein gene and the nontranslated 3' region of TMV. pTMV-CP-CAT was prepared as described by Dawson et al. (II) Briefly, pTMV-CP-CAT was constructed by cutting pTMV-S3-CAT-28 with HindIII (nt. 5081), blunting with Klenow fragment of DNA polymerase I, adding PstI and NsiI (nt. 6207), and ligating this 1434-bp fragment in the NsiI site (nt. 6207) of pTMV204. Correct ligation and orientation of each construct were checked by restriction mapping and sequencing.

Plant inoculations, CAT assays, RNA analysis and construction of cDNA clones of progeny were performed as described in Comparative Example I. pTMV-CP-CAT, the larger hybrid virus construct, contained a 628-nucleotide repeat of that portion of the 30K gene containing the coat protein subgenomic promoter and the origin of assembly. This construct should produce a virus, CP-CAT, 7822 nt long with a gene order of 126K, 183K, 30K, coat protein, and CAT. CP-

CAT replicated poorly. It produced necrotic lesions in Xanthi-nc that were small, approximately one-half the diameter of wild-type virus lesions, and their appearance was delayed by two days. Transmissibility of CP-CAT from these lesions was at a level approximately one-hundredth that of CAT-CP or wild-type TMV. No systemic symptoms appeared in Xanthi or N. sylvestris plants and the virus infection was transferrable only from inoculated leaves. Low but reproducible levels of CAT activity were found in CP-CAT-infected leaves. Since the replication of this chimeric virus was so impaired, characterization did not proceed any further.

In contrast to CAT-CP, when CP-CAT was allowed to replicate for extended periods in the systemic hosts, no wild-type-like virus symptoms ever were observed in upper leaves of plants and virus was never recovered from them, suggesting that this hybrid virus did not delete the inserted sequences in a manner to create a wild-type-like virus.

Comparative Example 3

A full-length DNA copy of the TMV genome is prepared and inserted into the PSTI site of pBR322 as described by Dawson, W.O. et al. (t). The viral coat protein gene is located at position 5711 of the TMV genome adjacent the 30k protein gene. The vector containing the DNA copy of the TMV genome is digested with the appropriate restriction enzymes and exonucleases to delete the coat protein coding sequence. For example, the coat protein coding sequence removed by partial digestion with ClaI and NsiI, followed by religation to reattach teh 3'-tail of the virus. Alternatively, the vector is cut at the 3' end of the viral nucleic acid. The viral DNA

is removed by digestion with <u>Bal</u>31 or exonuclease III up through the start codon of the coat protein coding sequence. A synthetic DNA sequence containing the sequence of the viral 3'-tail is then ligated to the remaining 5'-end. The deletion of the coding sequence for the viral coat protein is confirmed by isolating TMV RNA and using it to infect tobacco plants. The isolated TMV RNA is found to be non-infective under natural conditions.

The 314-bp Sau3A fragment (NH₂ terminus of the Tn5 NPTII gene) from pNEO was filled in with Klenow polymerase and ligated to SalI (pd[GGTCGACC]) linkers. It was then digested with SalI and PstI and inserted into PstI/SalI-digested pUC128 (55) to give pNU10. The pNEO plasmid was digested with AsuII, filled in with Klenow polymerase and ligated to XhoI linkers (pd[CCTCGAGG]) to give pNX1. The pNX1 was digested with XhoI, filled in with Klenow polymerase, digested with PstI and ligated into PstI/SmaI-digested pNU10 to give pNU116.

The <u>XhoI/SalI</u> fragment from pNU116 (NPTII sequences) is ligated adjacent the coat protein promoter. The resultant RFVNA containing the NPTII gene insert was applied to twelve <u>Nicotiana tabacum</u> (cv. Xanthi-NC), a cultivar that has been backcrossed to contain the N gene for TMV resistance and to twelve <u>N. tabacum</u> (cv. Xanthi), a cultivar that does not contain the N gene. In both tobacco cultivars, no systemic spread was observed in any inoculated plant. The <u>N. tabacum</u> (cv. Xanthi NC) showed the characteristic flecking spots on the inoculate leaf indicating resistance to the virus. The <u>N. tabacum</u> (cv. Xanthi) exhibited no flecking or systemic symptoms.

Comparative Example 4

A recombinant plant viral nucleic acid containing the NFTII coding sequence was prepared as described in Comparative Examples 1 and 3. The NFTII and coat protein coding sequences were each adjacent an "O" coat protein promoter. The presence of the coat protein gene should render the vector capable of being systemically spread.

The resultant RFVNA containing the NPTIIinserted gene was inoculated on twelve N. tabacum
(cv. Xanthi NC) and twelve N. tabacum (cv. Xanthi NC)
showed the flecking in each of the twelve plants, as
with Comparative Example 1. The N. tabacum (cv.
Xanthi) plants showed systemic spread of the vector
in all twelve plants.

Leaf discs from N. tabacum (cv. Xanthi) leaves were cultured on media containing kanamycin. None of the tissue survived in culture, indicating a loss or disfunction of the NFTII gene. Subsequent electron photomicroscopy of the present vector containing the NFTII gene recovered from the leaves of treated N. tabacum (cv. Xanthi) plants showed that the present vector had lost a section of the vector corresponding to the NPTII gene, indicating a breakage and recombination of the vector.

EXAMPLES OF THE PREFERRED EMBODIMENTS

The following examples further illustrate the present invention. These examples are intended merely to be illustrative of the present invention and are not to be construed as being limited.

EXAMPLE 1

Construction of Bacterial Plasmids. Numbers in parentheses refer to the TMV-U1 sequence (46). DNA

manipulations were performed essentially as described in (48). All plasmids were propagated in <u>E. coli</u> strain JM109 except for pTBN62 (DH5 α ; Gibco BRL; and H8101).

pTKU1 (Fia. 1). The 7.3 kb pTMV204 (4) PstI fragment (TMV-U1 genome and λ phage promoter from pPM1 (3) was subcloned into pUC19 to give pTP5. pTMV204 ApaI fragment (5455-6389) was ligated to oligonucleotides pd[CAGGTACCC] and d[GGGTACCTGGGCC], (SEQ ID No: 2), digested with KpnI (underlined within nucleotide sequence) and NcoI (5459) and ligated into NcoI/KpnI digested pTP5 to produce pTPK10. pTKUl was constructed by subcloning the 7.3 kb PstI/KpnI fragment from pTPK10 into PStI/KpnI-digested pUC118. pTKU1 contained a DNA copy of the entire TMV-VI genome downstream of the λ phage promoter from pPM1. KpnI digestion and in vitro transcription of pTKUI gave infectious TMV RNA. pTKUI was constructed because PstI sites in the odotoglossum ring spot virus (ORSV, sometimes referred to as TMV-0) coat protein, DHFR and NFTII ORFs prohibited the use of this restriction enzyme (employed to linearize pTMV204; 4) to digest plasmid DNA of the hybrid constructs and produce infectious in vitro transcripts.

pT82 (Fig. 1). pTMVS3-28 (45) was a derivative of pTMV204 in which the coat protein initiation codon was mutated to ACG and a XhoI site replaced the entire coat protein coding sequence. The 1.9 kb NcoI/SalI fragment (5459-SaIl site in p8R322) from pTMVS3-28 was ligated into NcoI/SalI-digested pNEO (56) to give pNS283. pBabsI was a 2.4 kb EcoRI cDNA clone from ORSV virion RNA with nucleotide, ORF and amino acid sequence similarities to TMV-UI (nts 4254-6370). A 680 bp pBabsl HincII/EarI (Klenow

polymerase infilled) fragment (containing the ORSV coat protein ORF and 203 bases upstream of its AUG) was ligated into the NstI site (6202; blunt-ended with T4 DNA polymerase) of pNS283 to produce pB31. The NcoI/SalI fragment from p831 was then ligated into the NcoI/SalI-digested pTMV204 (replacing the corresponding wild-type fragment 5459-SaIl site in pBR322) to give pTB281. pTB2 was constructed by ligating the BamHI/SplI fragment from pTB281 into BamHI/SplI-digested pTKUI (replacing the corresponding wild-type fragment 3332-6245).

pNC4X (57). pNC4X consisted of the R67 DHFR gene cloned into pUC8X. The plasmid contained a XhoI site eight bases upstream of the initiation codon for the DHFR gene. In addition, the stop codon and five bases of carboxy-terminal DHFR sequence were deleted and replaced by a SalI site.

pNU116. A 315 bp pNEO Sau3S (Klenow polymerase infilled) fragment (NH₂ terminus of Tn5 NPTII gene) was ligated to SalI (pd[GGTCGACC]) linkers, SalI/FstI digested, and inserted into FstI/SalI-digested pUC128 (55) to give pNU10. pNEO was digested with AsuII, infilled with Klenow polymerase and ligated to XhoI linkers (pd[CCTCGAGG]) to generate pNX1. pNUII6 was constructed by digesting pNX1 with XhoI, infilling with Klenow polymerase, digesting with PstI and ligating the resulting 632 bp fragment (COOH terminus of the Tn5 NPTII gene) into PstI/SmaI-digested pNU10. This manipulation of the NFTII gene removed an additional ATG codon 16 bases upstream of the initiation codon, the presence of which decreased NFTII activity in transformed plant cells (58).

pTBD4 and pTBN62 (Fia. 1). XhoI/SalI fragments
from pNC4X (DHFR sequence) and pNU116 (NPTII
sequence) respectively were ligated into the XhoI

site of pT82 in the same sense as the TMV coding sequences.

<u>In Vitro Transcription and Inoculation of</u>
<u>Plants.</u> Plants grown as in (45) were inoculated with in vitro transcripts TB2 (nt. 6602), T8D4 (nt. 6840) and TBN62 (nt. 7434) from <u>KpnI</u> digested pTBD2, pTBD4 and pTBN62, respectively. The in vitro transcription method was as previously described.

Analysis of Progeny Virion RNA. Virus purification was essentially as described by Gooding and Hebert (59) with one precipitation with polyethylene glycol (8% PEG, 0.1M NaCl; 0°C 1 hr) and one ultracentrifugation (151,000-235,000 x g; 90 min). Virion RNA was extracted by digesting 1 mg virus with 0.2 μg Froteinase K in 10mM Tris HCl, pH 7.5, lmM EDTA, 0.1% SDS at 37°C for 1 hr, followed by phenol/chloroform extractions. RNA samples were DMSO-denatured, glyoxalated, electrophoresed in 1% agarose gels and transferred to nitrocellulose (pore size 0.45 μ m; Schleicher and Schull; 48). transfers were probed with $[\alpha^{-35}S]$ -dATP (New England Nuclear) labelled (50) restriction fragments. RNase protection assays were as described in (48). TBD4-38 and pTBN62-38 contained BamHI/KpnI fragments (nts. 3332-6396) from pTBD4 and pTBN62, respectively, cloned into BamHI/KpnI-digested pBluescript SKI (Stratagene)

Immunological Detection of NPTII. Sample preparation and Western analysis were as described previously (45). Leaf samples were ground in liquid N₂ and extraction buffer (10% glycerol, 62.5mM Tris HCl pH 7, 5% mercaptoethanol, 5mM phenylmethylsulfonyl fluoride). Equivalent protein concentrations were determined and absolute concentrations estimated by Bradford assey

(Strategene; 61), with bovine serum albumin as standard. Western transfers were probed with antiserum to NPTII (1:500; 5 Prime, 3 Prime, Inc.) and then with alkaline phosphatase-conjugated goad anti-rabbit IgG (1:1000).

NFIII Activity Assavs. NPTII activity was detected by its phosphorylation of neomycin sulphate. Enzyme assays were as described in (62) except the extraction buffer was as described above and dilution series of purified NPTII (5 Prime, 3 Prime, Inc.) in healthy tissue were included.

Leaf Disc Assays to Screen for Resistance to
Kanamycin Sulphate. NPTII confers resistance to the
aminoglycoside kanamycin (56). Young systemic leaves
12 days post-inoculation were surface-sterilized and
washed in approximately 0.01% Tween 20 (5 min), 0.25%
sodium hypochlorite (2 min), 70% ethanol (30 sec),
distilled water (4 x 10 sec). Leaf discs were cut
from a leaf in pairs; one was placed on Murashige and
Skoog (MS) medium alone and the other on kanamycin
sulphate-supplemented MS medium. Plates were
incubated at 32°C with a photoperiod of 16 hours.
Leaf discs were transferred to freshly prepared
medium every seven days.

Mechanical inoculation of N. benthamiana plants with in vitro transcripts derived from DNA constructs pTB2, pTBD4 and pTBN62, respectively, resulted in symptomatic infection with virus of typical TMV shape and yield (1.5-5.8 mg virus/g tissue). Symptoms were less severe compared to TMV-UI-infected plants and consisted of plant stunting with mild chlorosis and distortion of systemic leaves. The sizes of virion RNA from systemically infected tissue of plants inoculated with TB2, TBD4 and TBN62, respectively, were consistent with predicted lengths of RNA

transcribed in vitro from the respective plasmids. These RNA species contained TMV sequences plus their respective bacterial gene inserts. Probes complementary to the manipulated portion of the respective genomes were protected in RNase protection assays by progeny TBD4 and TBN62 viral RNAs. indicated that the precise and rapid deletion of inserted sequences which had been a problem with previous constructs (11) did not occur with TBD4 or It was hypothesized that with the prevously reported constructs, foreign inserts were deleted due to recomb ination between repeated subgenomic promoter sequences (11) With TBD4 and TBN62, such repeated sequences were reduced by employing heterologous subgenomic mRNA promoters. Additional bands that were seen and were smaller than the probe and smaller than the full-length viral RNA might represent alterations within a portion of the TBN62 population, although in this case the relative proportion of full-length and additional smaller bands was unchanged following a subsequent passage.

The sequence stability of TBD4 and TBN62 virion RNA was examined in serial passages through N. benthamiana. Plants were inoculated with two and four independent in vitro transcript ion reactions from pTBD4 and pTBN62, respectively, and systemically infected leaf tissue was serially passaged every 11-12 days. After 48 days of systemic infection, full-length virion RNA of TBD4 including the DHFR sequences was still detected by Northern transfer hybridization, and still protected probes complementary to the manipulated portion of the genome in RNase protection assays. Five clonal populations of virion RNA were derived from TBD4-infected plants propagated for 170 days (one series

involving 10 passages) by isolation of local lesions on N. tabacum Xanthi-nc. The concensus DHFR sequence for three of the populations corresponded with the published DHFR sequence except for a translationally silent third base change (U->C) at nucleotide 72 of the coding sequence. The nucleotide change at position 72 of the DHFR coding sequence was not evident in progeny RNA from TBD4 infected plants propagated for 48 days. Virion RNA from plants serially infected with TBN62 was less stable with different portions of the NPTII sequence being deleted in each of the independent series of passages. The time of loss of these sequences varied between after the first passage (12-24 days) and the third passage (36->47 days). The reason for the occurrence of deletions in the NPTII sequence of TBN62 is not known. However, on the basis of the stability of the DHFR sequences in TBD4, such instability of inserted foreign sequences would not seem to be an intrinsic feature of the expression vector TB2. In contrast, such deletions might be dictated by the nucleotide composition of the inserted foreign sequences themselves. Similar instabilities among DNA plant virus vectors have been seen.

A commercial source of antiserum and sensitive enzymatic assays for the extensively used selectable marker NPTII (62) allowed further analysis of tissue infected with TBN62. Western blot analysis, enzyme activity, and leaf disc assays demonstrated the presence of functional NPTII enzyme and its phenotypic expression in plant tissue systemically infected with TBN62 but not in TB2-infected or healthy plants. NPTII protein and enzyme activity

was even detected in some TBN62-infected plants propagated for 36 days.

It was evident that the levels of extractable NPTII protein were considerably lower than coat protein, the most highly expressed TMV protein. Such low levels could be a reflection of the relative stabilities or partitioning of the respective proteins in plant cells, or might be due to one or more aspects of the vector or foreign gene sequences affecting the synthesis of subgenomic mRNA or posttranscriptional expression of the reporter gene. relatively high yield of virus from plants infected with the vector constructs would seem to preclude a dramatic reduction in the efficiency of virus replication. However, one possibility for low expression might be the position of the reporter gene relative to the 3' terminus of the genome. amount of the 30kDa protein produced by different mutants of TMV has been shown to be inversely proportional to the distance the 30kDa protein ORF was from the 3' terminus of the genome. This relationship was consistent with the observations of French and Ahlquist (63), i.e., that the level of subgenomic RNA from brome mosaic virus RNA 3 was progressively greater the closer the promoter was inserted to the 3' terminus.

EXAMPLE 2

Although the RPM of Example 1 is capable of systemic spread in N. benthaniana, it is incapable of systemic spread in N. tabacum. This example describes the synthesis of RPM which is capable of systemic spread in N. tabacum.

The O-coat protein coding sequence contained in pTB2 was cut from pTB2 by digestion with AhaIII. The

UI-coat protein coding sequence was removed from pTMV2O4 by digestion with <u>Aha</u>III and inserted into <u>Aha</u>III-digested pTB2 to produce vector pT8U5 (Fig. I)

The <u>XhoI/SalI</u> fragments from pNC4X (DHFR sequence) and pNU116 (NPTII sequence), respectively, are ligated into the <u>XhoI</u> site of pTBU5 in the same sense as the TMV coding sequences. <u>N. tabacum</u> plants are inoculated and analyzed as described in Example 1. Functional enzymes are seen in the systemically infected plants but not in the control plants.

EXAMPLE 3

This example describes the synthesis of RPVNA in which the native coat protein gene is under control of its native subgenomic promoter and a non-native subgenomic promoter has been inserted to drive the expression of non-native nucleic acid.

The TMV-O promoter and the TMV-UI coat protein sequence are removed from pTB2 by digesting with <u>Xho</u>I and <u>Kpn</u>I. The <u>Xho</u>I end is converted to a <u>Pst</u>I site by blunt-ending and adding a <u>Pst</u>I linker. This <u>Pst</u>I/<u>Kpn</u>I fragment is subcloned into a Bluescript vector. Two subclones of this Bluescript vector are created by site-directed mutagenesis as follows:

Bluescript Sub I is prepared by using PCT techniques to create a site-specific fragment that will force a mutation at the ATG (coat protein) start site and create a XhoI site near the ATG site.

Bluescript Sub 2 is prepared by using PCR techniques to create a site-specific fragment that will force a mutation at the TAA (coat protein) stop site and create a XhoI site near the TAA site. A PstI/XhoI cut of the Bluescript Sub I and a XhoI/KpnI cut of the Bluescript Sub 2 will give two fragments that can

be ligated, giving a PstI/KpnI fragment that has a XhoI cloning insert site that is downstream from the TMV-O promoter. This PstI/KpnI fragment is inserted into the pTKUI vector that has had a NsiI/KpnI fragment removed. (PstI end can be ligated to NsiI). The resulting clone will be pTKUI-a with a TMV-O promoter on the 3' side and a XhoI insert site, into which can be inserted a gene-of-choice, that will be driven by the TMV-O promoter.

The <u>XhoI/SalI</u> fragments from pNC4X (DHFR sequence) and pNU116 (NPTII sequence), respectively, are ligated into the <u>XhoI</u> site of pTBU1-a in the same sense as the TMV coding sequences. <u>N. tabacum</u> plants are inoculated and analyzed as described in Example 1. Functional enzymes are seen in the systemically infected plants but not in the control plants.

EXAMPLE 4

Additional DNA coding sequences were prepared for insertion into RVPNAs having either the O-coat protein (Example 1) or the U1-coat protein gene (Example 2). In each instance, the coding sequence was synthesized to contain the XhoI site of pTB2 (Example 1) or pTBU5 (Example 2), in the same sense as the coding sequence.

Standard procedures were used to trans form the plasmids into <u>E. coli</u> and to isolate the DNA from an overnight culture. Following extraction of the plasmid DNA, an RNA copy of the TB2 or TBV5 vector (with or without the gene of choice) was made using a DNA-directed RNA polymerase. The RNA was capped during the reaction by adding m⁷GpppG₄ during the transcription reaction, as previously published. This RNA was then used to inoculate a tobacco plant.

Standard virus isolation techniques can be used to purify large concentrations of the transient vector for inoculations of multiple numbers of plants.

A coding sequence for Chinese cucumber α -trichosanthin containing <u>Xho</u>I linkers is shown in SEQ ID NO: 3, with the corresponding protein as SEQ ID NO: 4.

A coding sequence for rice α -amylase containing <u>Xho</u>I linkers is shown in SEQ ID NO: 5, with the corresponding protein as SEQ ID NO: 6. This sequence was prepared as follows:

The yeast expression vector pEno/I03 64 was digested with HindIII and treated with mung bean exonuclease to remove the single-stranded DNA overhang. The .16 kb HindIII (blunt end) fragment containing the entire rice α-amylase cDNA 05103 65 1990; GenBank accession number M24286) was digested with ScaI and linkered with a XhoI oligonucleotide (5'CCTCGAGG 3'). The modified α-amylase cDNA fragment was isolated using low-melt agarose gel electrophoresis, subcloned into an alkaline phosphatase treated XhoI site in pBluescript KS+(Stratagene, La Jolla, Calif.), and maintained in E. coli K-12 strain C-600.

A rice α -amylase coding sequence containing a short 3'-untranslated region was prepared as follows:

The <u>E. coli</u> vector pVC18/13 (64) was digested with <u>KpnI</u>, <u>Xho</u>I and treated with ExoIII and mung bean exonuclease. The modified plasmid was treated with DNA poll, DNA ligase, and transformed into C-600. An isolate, clone pUC18/3 #8, had a 3' deletion that was very close to the stop codon of 05103. This plasmid was digested with <u>EcoRI</u>, treated with mung bean exonuclease, and linkered with a <u>Xho</u>I oligonucleotide (5'CCTCGAGG 3'). A 1.4 Kb <u>HindIII-XhoI</u> fragment from

the resulting plasmid (pUC18/3 #8X) was isolated using low melt agarose gel electrophoresis, subcloned into pBluescript KS- (Stratagene, La Jolla, Calif.) and maintained in <u>E. coli</u> K-12 strains C-600 and JM109. The deletion was sequenced by dideoxy termination using single-stranded templates. The deletion was determined to reside 14 bp past the rice a-amylase stop codon. Plasmid pUC18/3 #8X was digested with <u>HindIII</u>, treated with mung bean exonuclease, and linkered with a <u>XhoI</u> oligonucleotide (5 'CCTCGAGG 3') A 1.4 Kb <u>XhoI</u> fragment was isolated by trough elution, subcloned into an alkaline phosphatase-treated <u>XhoI</u> site in pBluescript KS+, and maintained in JM109.

A sequencing containing the coding sequence for human α -hemoglobin or β -hemoglobin and transit peptide of petunia EFSP synthase is shown in SEQ ID NO: 7 or SEQ ID NO: 8, and corresponding protein sequences as SEQ ID NO: 9 and SEQ ID NO: 10, respectively.

Purified protein extracts from N. benthamiana treated with a recombinant plant viral nucleic acid containing the gene for α -trichosanthin, prepared in accordance with Example 1, were separated using polyacrylamide gel electrophoresis and probed with antibodies specific for α -trichosanthin using standard procedures for Western analysis. Figure 2 is an autoradiograph of the gels which demonstrates production of processed α -trichosanthin protein in plants treated with a recombinant plant viral nucleic acid containing the gene for α -trichosanthin.

WO 93/03161 PCT/US92/06359

-64-

EXAMPLE 5

Field Tests

The field site design contained two experiments (1 and 2). Experiment 1 was a typical row crop configuration that contained untreated border rows (8) of tobacco on all outside perimeter rows as well as internal rows. In addition, every fourth row was a spacer row (S) that was left unplanted in order to allow large farm equipment to access the field (e.g., for spraying pesticides) without coming into direct contact with any of the treated rows (T) Each inoculation was administered by direct hand application of the vector to a single leaf of an individual plant. No spray inoculum was used.

Experiment 2 was a typical plantbed configuration. A high density of plants per square foot was grown at a uniform height by frequent clipping of the plantbed using a modified mower attached to a tractor power takeoff. This experiment contained a complete perimeter border of plantbeds that was not inoculated with the vectors.

Inoculation of the treated plantbeds was made using a downward-directed spray through the modified mower blade assembly and administered so as to prevent overspray to adjacent plantbeds.

Experiment 1 was a split-plot design using row culture with seven genotypes as main plots in randomized blocks and four replications. Each plot was 13 feet long and consisted of three rows, with only the middle three or four plants of each center row used for testing. Rows were four feet on center and plants spaced 20 to 22 inches in the row.

Experiment 2 was a randomized complete block design using plantbed culture with four genotypes and

three replications. Each plot consist d of a 4-foot by 12-foot plantbed.

Genotypes. Experiment 1: (Nicotiana tabacum)
K-326, Sp G-28, TI-560, Md-609, Galpao, Wisc-503B and
Nicotiana benthamiana.

Experiment 2: (Nicotiana tabacum) K-326, TI-560, Md-609, Galpao.

Chemical Fertilization. Experiment 1: 800 lbs 6-12-18 after transplanting; 100 lbs 33-0-0 after first harvest; 200 lbs 15-0-14 after second harvest.

Experiment 2: 2400 labs 12-6-6 at time of plantbed formation; 300 labs 33-0-0 after first harvest; 670 lbs 15-0-14 after second harvest.

<u>Clipping</u>. Experiment 2 was clipped twice a week for two weeks, to impart uniformity to the plants.

Weed, Insect and Disease Control. Experiment 1: Prior to forming rows, Paarlan 6B (1 qt/A), Temik 15G (201b/A) and Ridomil (2 qts/A) were broadcast-applied and incorporated by disking. During row formation, Telone C-17 (10.5 gal/A) was applied. After transplanting, Dipel (1/2 lb/A) was applied to control budworms and hornworms. Orthene (2/3 lb/A) was applied to control aphids and hornworms as necessary.

Experiment 2: Ridomil 2G (1 qt/A; 1 oz/150 sq yds) was applied at seeding and at weekly intervals beginning 60-70 days after seeding (as needed). Carbamate 76WP (3 lb/100 gal water) was also used as foliar spray as needed in the initial plantbed stage, to control Anthracnose and Damping-off diseases. At normal transplanting size, Dipel (1/2 lb/A) was applied. Orthene (2/3 lb/A) was applied to control aphids and hornworms as necessary.

Transplanting. Experiment 1 was transplanted using seedlings pulled from the plantbeds of Experiment 2.

<u>Inoculation</u>. Experiment 1: A single leaf on each non-control plant was hand-inoculated with a selected recombinant plant viral nucleic acid containing NPT II, α -trichosanthin or rice α -amylase. Each individual plant was inoculated with a single vector.

Experiment 2: The plants were inoculated with the vectors described in Experiment 1, using a spray applied through the deck of the clipping mower while the plants are being clipped a final time. Each non-control plot received only a single vector construct. Control plants received no inoculation with any vector.

Data Collection. Experiment 1: Sampling of both inoculated and control plant leaves was conducted on a schedule (approximately weekly) during first growth until plants were approximately 30 inches tall. Plants were then cut (harvest 1) with a rotary brush blade to leave six inches of stalk exposed above the ground. The plants were then allowed to continue growth (second growth) to a height of approximately 30 inches. Leaf samples were taken just before harvest 2. This procedure for cutting, growth and sampling was repeated for third growth and for fourth growth, if detectable amounts of the genes of interest inserted into the vectors were found.

Experiment 2: Sampling of 10 plants from each plot was conducted on a schedule (approximately weekly) from inoculation to harvest 1 and from harvest 1 until harvest 2. Following harvest 2, sampling was conducted only at harvest 3.

Sample Size and Analytical Methods. A 1.6 cm disk was excised from a single leaf near the apex of the plant. Each leaf disk was placed either in a 25 ml glass vial with screw cap and containing absolute ethanol or in a sealable plastic bag.

Leaf discs were either preserved in absolute ethanol or lyophilized. Depending on the specific gene product to be detected, leaf samples were prepared according to standard techniques for Northern or Western blot analyses or specific enzyme activity.

During first growth, visual monitoring of the pI ants treated with the RPVNA were conducted to observe any external phenotypic expression of the vector system. In some cases, the phenotypic expression was typical of Tobacco Mosaic Virus infections (lighter and darker "mosaic" patterns in the leaf). In other cases, the only symptoms seen were on the inoculated leaf, which included white or brown speckels of approximately 2mm in diameter and/or suppression of the central vein elongation of the leaf.

EXAMPLE 6

A full-length DNA copy of the OMV genome is prepared as described by Dawson, W.O. et al. (4). The vector containing the DNA copy of the OMV genome is digested with the appropriate restriction enzymes or suitable exonucleases to delete the coat protein coding sequence. The deletion of the coding sequence for the viral coat protein is confirmed by isolating OMV and using it to infect germinating barley plants. The isolated OMV RNA is incapable of spreading beyond the lesion under natural conditions. A vector

WO 93/03161 PCT/US92/06359

-68-

containing the OMV sequences is prepared as described in Examples 1-3.

EXAMPLE 7

A full-length DNA copy of the genome is prepared as described by Dawson, W.O. et al. (4). The vector containing the DNA copy of the ENV genome is digested with the appropriate restriction enzymes or suitable exonucleases so as to delete the coat protein coding sequence. The deletion of the coding sequence for the viral coat protein is confirmed by isolating RNV RNA and using it to infect germinating barley plants. The isolated is incapable of spreading beyond the lesion under natural conditions. A vector containing the OMV sequences is prepared as described in Examples 1-3.

EXAMPLE 8

A full-length DNA copy of the PVY or PVX genome is prepared as described by Dawson, W.O. et al. (4). The vector containing the DNA copy of the PVY or PVX genome is digested with the appropriate restriction enzymes or suitable exonucleases to delete the coat protein coding sequence. The deletion of the coding sequence for the viral coat protein is confirmed by isolating PVY or PVX ENA and using it to infect potato plants. The isolated PVY or PVX RNA is incapable of spreading beyond the lesion under natural conditions. A vector containing the OMV sequences is prepared as described in Examples 1-3.

EXAMPLE 9

A full-length DNA copy of the maize streak virus (MSV) genome is prepared as described by Dawson, W.O. et al. (4). The vector containing the DNA copy of the Msv genome is digested with appropriate restriction enzymes or suitable exonucleases to delete the coat protein coding sequence. Deletion of the coding sequence for the viral coat protein is confirmed by isolating MSV and using it to infect potato plants. The isolated MSV is incapable of spreading beyond the lesion under natural conditions. A vector containing the OMV sequences is prepared as described in Examples 1-3.

EXAMPLE 10

A full-length DNA copy of the TGMV genome is prepared as described by Dawson, W.O. et al. (4). The vector containing the DNA copy of the TGMV genome is digested with the appropriate restriction enzymes or suitable exonucleases to delete the coat protein coding sequence. The deletion of the coding sequence for the viral coat protein is confirmed by isolating TGMV RNA and using it to infect potato plants. The isolated TGMV RNA is incapable of spreading beyond the lesion under natural conditions. A vector containing the TGMA sequences is prepared as described in Examples 1-3.

EXAMPLE 11

The coding sequence for beta-cyclodextrin glucotransferase is isolated from alkalophilic

Bacillus sp. strain No. 38-2 in the following manner:

PCT/US92/06359

The chromosomal DNA of strain No. 38-2 (66) is partially cleaved with Sau3AI, and the fragments ligated in BamHI-digested pBR322. A transformant carrying plasmid pCS115, which contains a 3.2 kb DNA fragment from the genome of the producing strain, has the CGT activity. The CGT produced by this transformant gives one line of precipitation which fuses completely with that for the No. 38-2 CGT by an Ouchterlony double-diffusion test. The nucleotide sequence of the fragment is found by the dideoxy chain termination reaction using pUC19, and the exonuclease deletion method (67). The nucleotide sequence of the fragment shows a single open reading frame corresponding to the CGT gene. A protein with a molecular mass of 66 kDal could be translated from this open reading frame of 1758 bp. For the detailed nucleotide sequence, see Hanamoto, T. et al. (66).

The sequence of the N-terminal amino acids of the extracellular form of CGT is found with a peptide sequencer. NH₂-Ala-Pro-Asp-Thr-Ser-Val-Ser-A5n-Lys-Gln-Asn-Phe-Ser-Thr-Asp-Val-Ile (SEQ ID NO: 6) is identical to that deduced from the DNA sequence (residues 1 to 17). This result suggests that 27 amino acid residues (residues -27 to -1) represent a signal peptide which is removed during secretion of CGT. The molecular weight of the matured CGT calculated from the DNA sequence is 63,318.

A probe is prepared based on a portion of the amino acid sequence of cyclodextrin glucanotransferase and used to isolate the coding sequence for this enzyme. Alternatively, the beta cyclodextrin glucotransferase coding sequence is isolated following reverse transcription. The fragment containing the coding sequence is isolated and cloned adjacent the subgenomic promoter of the

native viral coat protein gene in the vectors prepared in Examples 6-10.

EXAMPLE 12

The RPVNA of Example 11 is used to infect corn plants (viruses based on OMV, RNV, or TGMV) or potato plants (viruses based on PVY or PVX). The infected plants are grown under normal growth conditions. The plants produce cyclodextrin glucotransferase which catalyzes the conversion of starch to cyclodextrin in the plant tissue. The cyclodextrin is isolated by conventional techniques.

EXAMPLE 13

A. The coding sequence for an esterase is isolated from <u>Bacillus subtilis</u> Thai 1-8 (CBS 679.85) as follows. The positive selection vector pUN121 (68) is used. This vector carries an ampicillin resistance gene, a tetracycline resistance gene and a C₁-repressor gene. Transcription of the tetracycline gene is prevented by the gene product of the C₁-repressor gene. Insertion of foreign DNA into the <u>Bcl</u>I site of the C₁-repressor gene results in activation of the tetracycline gene. This allows positive selection of recombinants on ampicillin/tetracycline agar plates.

Partially <u>Sau</u>3a-digested <u>Bacillus subtillis</u> Thai 1-8 DNA is mixed with <u>Bcl</u>I-digested pUN121 DNA. After recirculation by the use of polynucleotide ligase, the DNA mixture is introduced into <u>E. coli</u> DH1 (ATCC No. 33849) using the CaCl₂ transformation procedure. One thousand <u>E. coli</u> colonies are obtained which are resistant to ampicillin and

tetracycline. All transformants are stored and replica-plated according to Gergan et al. (69). Replicated colonies are screened using a soft agar overlay technique, based on a previously described procedure to detect esterase activity (70). Essentially, a mixture of 0.5% low-melting agarose, 0.5M potassium phosphate (pH 7.5), 0.5 mg/l β naphthyl acetate and 0.5 mg/ml fast-blue is spread over the transformants. Within a few minutes, colonies with esterase or lipase activity develop purple color. Such colonies are grown overnight in 2x YT (16 g/l Bactotryptone, 10 g/l yeast extract, 5 q/l NaCl) medium and subsequently assayed for their ability to convert S-naproxen ester to S-naproxen (the method of Example 1 of EP-A 0233656). One E. <u>coli</u> transformant is able to convert S-naproxen ester. The plasmid isolated from this transformant, which is called pNAPT-2 (CBS 67186). Its size is 9.4 kb.

HindIII restriction enzyme fragments of pNAPT-2 are ligated into pPNEO/ori. This is performed as described below. pPNeo/ori is constructed by ligating the 2.7 kb EcoRI/SmaI restriction fragment of pUCl9 to the 2.5 kb EcoRI-SnaBI restriction fragment of pUBl10. The resulting shuttle plasmid, pPNeo/ori (5.2 kb) has the capacity to replicate both in E.coli and in Bacillus species due to the presence of the pUCl9 origin, and the pUBl10 origin. In addition, pPNeo/ori carries a gene encoding ampicillin resistance and a gene encoding neomycin resistance.

For subcloning, <u>HindIII</u>-digested pNAPT-2 is mixed with <u>HindIII</u>-digested pPNeo/ori and ligated. The mixture is transformed to <u>E. coli</u> JM101 hsds as described (Maniatis et al., supra). <u>E. coli</u> JM101

hsds is obtained fr m the Phabagen collection (Accession No. PC 2493, Utrecht, The Netherlands). Colonies capable of hydrolyzing β -naphthyl acetate are selected as described in Example 56 of EPA 0 233 656. From two positive colonies, pNAPT-7 and pNAPT-8 plasmid DNA is isolated and characterized in detail by determining several restriction enzyme recognition positions.

B. The coding sequence for an \underline{E} . \underline{coli} esterase is prepared as follows:

Plasmids pIP1100 (isolated from <u>E. coli</u> BM 2195) and pBR322 are mixed, digested with AvaI, ligated and transformed into E. coli, and clones are selected on Em (200 /g/ml). Transformants resistant to Ap and Em but also to Sm are analyzed by agarose gel electrophoresis of crude lysates. The transformant harboring the smallest hybrid plasmid is selected, its plasmid DNA is digested with AvaI, and the 3.5 kb pIP1100 insert is purified and partially digested with Sau3A. The restriction fragments obtained are cloned into the BamHI site of pBR322 and transformants selected on Em are replica-plated on Sm. The plasmid content of transformants resistant only to Ap and Em is analyzed by agarose gel electrophoresis. DNA from the smallest hybrid, pAT63, is purified and analyzed by agarose gel electrophoresis after digestions with Sau3A, EcoRI, PstI or HindIII-BamHI endonucleases (not shown). Plasmid pAT63 consists of pBR322 plus a 1.66 kb pIP1100 DNA insert. Purified EcoRI-HindIII (1750bp) and BamHI-PstI (970-bp) fragments of pAT63 are subcloned into pUC8 and found not to confer resistance to Em.

The HpaII-BamHI fragment of pAT63 is sequenced according by the Sanger technique. The complete sequence is shown in Ounissi, H. et al. (71).

C. The coding sequence from acylase is isolated from <u>Arthrobacter viscosus</u> 8895GU, ATCC 27277 follows.

A gene library of A. viscosus 8895GU is constructed by inserting EcoRI-cleaved A. viscosus chromosomal DNA into the EcoRI cleavage site of pACYC184. The vector DNA and A. viscosus DNA are both digested with EcoRI. The 5' end of the vector DNA is dephosphorylated with calf intestinal alkaline phosphatase. Dephosphoroylated vector DNA and digested A. viscosus DNA are incubated with T4 DNA ligase and transformed into E. coli HB101. Transformed colonies of E. coli were screened by the Serratia marcescens overlay technique. Penicillin G was added to the medium. S. marcescens is sensitive to the deacylation product of penicillin G, 6aminopenicillamic acid (6-APA). Colonies of transformed E. coli will produce areas of S. marcescens inhibition in overnight cultures. plasmid carried by transformed E. coli is referred to as pHYM-1. The plasmid having opposite DNA orientation is designated pHYM-2 (72).

D. A coding sequence for human gastric lipase mRNA is prepared by guanidinium isothiocyanate extraction of frozen tissue. Polyadenylated RNA is isolated by oligo(dT)-cellulose chromatography. cDNA is prepared from human stomach mRNA by procedures well known in the art. cDNA is annealed to PstI-cut dG-tailed pBR322. The hybrid plasmid is transformed into E. coli DHI. Transformants are screened by colony hybridization on nitrocellulose filters. The probe used is synthesized from the rat lingual lipase

gene and labeled by nick translation. Positive colonies are grown up and plasmids are analyzed by restriction endonuclease mapping.

An exterase acylase or lopase gene prepared as described above is removed from the appropriate vector, blunt-ended using mung bean nuclease or DNA polymerase I, and <u>Xho</u>I linkers added. This esterase with <u>Xho</u>I linkers is cleaved with <u>Xho</u>I and inserted into the vertors described in Examples 1-3 or 6-10 Infection of the appropriate host plants by the RPVNA prepared in accordance with Example 2 results in the synthesis of esterase, acylase or lipase in the plant tissue. The enzyme is isolated and purified by conventional techniques and used to prepare stereospecific compounds.

EXAMPLE 14

The coding sequence for CMS-T is isolated from a BamHI maize mtDNA library as described by Dewey, R.E., et al. (73). The ORF-13 coding sequence is isolated by restriction endonucleuse digestion followed by 5'-exonuclease digestion to the start codon. alternatively, a restriction site is engineered adjacent the start codon of the ORF-13 coding sequence by site-directed oligonucleotide mutagenesis. Digestion with the appropriate restriction enzyme yields the coding sequence for ORF-13. The fragment containing the ORF-13 coding sequence is isolated and cloned adjacent the promoter of the native viral coat protein gene in the vectors prepared in Examples 6, 7 and 10.

Maize plants are infected by teh RPVNA prepared in accordance with Example 1. The infected plants

are grown under normal growth conditions. The plants produce cms-T which induces male sterility in the infected maize plants.

EXAMPLE 15

The coding sequence of $\underline{S_2}$ -protein (for self-incompatibility) is isolated from Nicotiana alata as described in EP-A 0 222 526. The $\underline{S_2}$ -protein coding sequence is isolated by restriction endonucleuse digestion followed by 5'-exonuclease digestion to the start codon. Alternatively, a restriction site is engineered adjacent the start codon of the $\underline{S_2}$ -protein coding sequence by site-directed oligonucleotide mutagenesis. Digestion with the appropriate restriction enzyme yields the coding sequence for $\underline{S_2}$ -protein. The fragment containing the $\underline{S_2}$ -protein coding sequence is isolated and cloned adjacent the promoter of the viral coat protein gene in the vectors prepared in Examples 1-3.

Tobacco plants are infected by the RPVNA prepared in accordance with Example 1, prior to pollen formation. The infected plants are grown under normal growth conditions. The plants produce S-protein which induces male sterility via the self-incompatibility mechanism.

The following example demonstrates that high levels of therapeutic proteins can be expressed using the plant RNA viral vectors of the present invention.

EXAMPLE 16

Rapid and High Level Expression of Biologically Active α-trichosanthin in Transfected Plants Using a Novel RNA Viral Vector

Trichosanthin is a eukaryotic ribosome inactivating protein found in the roots of a Chinese medicinal plant (74). In <u>Trichosanthes kirilowii</u> Maximowicz, α-trichosanthin is a monomeric protein which catalyzes the cleavage of an N-glycosidic bond in 28S rRNA (75,76). This reaction inhibits protein synthesis by affecting the ability of the 60S ribosomal subunit to interact with elongation factors. The mature compound has an approximate relative molecular mass of 27 kDa and is initially produced as a preprotein (77). During its biosynthesis, a putative 23 amino acid secretory signal peptide is removed and a 19 amino acid peptide is probably excised from the carboxy terminus.

Purified <u>T. kirilowii</u> derived α-trichosanthin causes a concentration-dependent inhibition of HIV replication in acutely infected CD4+ lymphoid cells, and in chronically infected macrophages (78,79). This compound is currently being evaluated in clinical studies as a potential therapeutic drug in the treatment for HIV infection (80). The exact mechanism of anti-HIV infection by α-trichosanthin is not known. Amino acids involved in catalysis and inhibition of HIV replication may be identified using site directed mutagenesis. Detailed structure/function analysis will require an abundant source of recombinant protein as well as a rapid method for generating and analyzing mutants. Although the expression of α -trichosanthin in E. coli has been reported previously (81, 97), the amount

synthesized was low (approximat ly 0.01% total cellular protein), the carboxy terminal extension was not removed, and the biological activity of the compound was not determined.

Tobamoviruses, whose genomes consist of one plus-sense RNA strand of approximately 6.4 kb, have been used to produce heterologous proteins. RNA transcripts from viral cDNA clones serve as infectious templates, encoding proteins involved in RNA replication, movement, and encapsidation (82). Subgenomic RNA for messenger RNA synthesis is controlled by internal promoters located on the TMV RNA viruses have minus-sense RNA strand (83). been used previously to express Leu-enkephlin in tobacco protoplasts (84) and bacterial chloramphenicol acetyltransferase in inoculated tobacco leaves (85,86). These previous attempts to express foreign genes have resulted in either unstable constructs or loss of long distance viral movement. Recently, Nicotiana benthamiana plants transfected with a hybrid virus consisting of tobacco mosaic virus, strain U1 (TMV-U1) and an additional RNA subgenomic promoter from odontoglossum ringspot virus (ORSV) produce a systemic and stable expression of neomycin phosphotransferase (87).

Construction of pBGC152

The plasmid pSP6-TKUI contains the entire TMV-U1 genome fused to the SP6 promoter by oligonucleotide directed mutagenesis and inserted into pUC118 as a XhoI/KpnI fragment. The sequence of the mutagenesis primer used to attach the SP6 promoter sequence to the TMV genome is: 5'-GGGCTCGAGATTTAGGTGACACTATAGTATTTTTACAACAATTACCA-3' wherein the XhoI site is in italics, the SP6 promoter is in boldface and the TMV sequence is

underlined. The primer was attched to a TMV subclone called pC48 (Raffo, et al., Virology 184: 277-289 (1991)). The promoter was attached by PCR using the above primer and a primer complementary to TMV sequences 5673 to 5692. This amplification produced a fragment of ca. 614bp, which was then digested with XhoI and EcoRI (TMV 270) to produce a ca. 292 bp fragment which was then subcloned into similarly cut pUC129 resulting in plasmid pSP6-T1.

pSP6-T1 was cut with <u>XhoI</u> and <u>XmaI</u> (a <u>SmaI</u> isoschizomer which cuts at TMV 256) and the resulting ca. 278 bp fragment was ligated into pTKU1 (Donson, et al. <u>Proc. Natl. Acad. Sci. U.S.A. 88</u>:7204-7208 (1991)) which had been modified by cutting at the unique <u>PstI</u> site at the 5' end of the genome, blunting with T4 DNA polymerase, followed by the addition of <u>XhoI</u> linkers. This resulted in the infectious clone pSP6-TKU1 and <u>XmaI</u> digested.

As shown in FIG. 7, the ECORI site in pBR322 was mutagenized to a KpnI site using ECORI, DNA polymerase (Klenow), and KpnI linkers. A KpnI\BamHI fragment of the resulting plasmid, pBSG121, was substituted with a KpnI\BamHI fragment of pTB2 (ATCC No. 75,280 deposited July 24, 1992). A SalI/KpnI fragment of the resulting plasmid, pBSG122, was substituted with a KhoI/KpnI fragment of pSP6-TKUI (also known as T1) which resulted in plasmid pBGC150.

A BamHI/KpnI fragment of pBGC150 was substituted with a BamHI/-KpnI fragment of pTB2/Q resulting in plasmid pBGC152. pTB2/Q was constructed beginning with plasmid pQ21D (ATCC No. 67907) described in Piatak, Jr., et al. U.S. Patent No. 5,128,460, the contents of which are incorporated herein by reference. The plasmid "clone 5B" containing a PCR amplified 0.88 kb XhoI fragment of the TCS sequence

in pQ21D was obtained using oligonucleotide mutagenesis to introduce <u>Xho</u>I cloning sites at the start and stop codons of pQ21D such that the following sequence was obtained: 5'-CTCGAGGATG ATC ----//--- ATT TAG TAA CTCGAG-3' (<u>Xho</u>I site in italics). A 0.88 kb <u>Xho</u>I fragment from "clone B" was subcloned into the <u>Xho</u>I site of plasmid pTB2 in the sense orientation to create plasmid pTB2/Q.

In vitro transcriptions, inoculations, and analysis of transfected plants

N. benthamiana plants were inoculated with in vitro transcripts of KpnI digested pBGC152 as described previously (89). Virions were isolated from N. benthamiana leaves infected with BGC152 transcripts, stained with 2% aqueous uranyl acetate, and transmission electron micrographs were taken using a Zeiss CEM902 instrument.

Purification, immunological detection, and in vitro assay of α-trichosanthin

Two weeks after inoculation, total soluble protein was isolated from 3.0 grams of upper, non-inoculated N. benthamiana leaf tissue. The leaves were frozen in liquid nitrogen and ground in 3 mls of 5% 2-mercaptoethanol, 10 mM EDTA, 50 mM potassium phosphate, pH 6.0. The suspension was centrifuged and the supernatant, containing recombinant α-trichosanthin, was loaded on to a Sephadex G-50 column equilibrated with 2 mM NaCl, 50 mM potassium phosphate, pH 6.0. The sample was then bound to a Sepharose-S Fast Flow ion exchange column. Alphatrichosanthin was eluted with a linear gradient of 0.002-1 M NaCl in 50 mM potassium phosphate, pH 6.0. Fractions containing α-trichosanthin were concentrated with a Centricon-20 (Amicon) and the

buffer was xchang d by diafiltration (Centricon-10, 50 mM potassium phosphate, pH 6.0, 1.7 M ammonium sulfate). The sample was then loaded on a HR5/5 alkyl superose FPLC column (Pharmacia) and eluted with a linear ammonium sulfate gradient (1.7-0 M ammonium sulfate in 50 mM potassium phosphate, pH 6.0). Total soluble plant protein concentrations were determined (90) using BSA as a standard. The concentration of α -trichosanthin was determined using the molar extinction coefficient of $E_{280} = 1.43$. purified proteins were analyzed on a 0.1 % SDS, 12.5% polyacrylamide gel (91) and transfered by electroblotting for 1 hour to a nitrocellulose membrane (92). The blotted membrane was incubated for 1 hour with a 2000-fold dilution of goat anti- α trichosanthin antiserum. The enhanced chemiluminescence horseradish peroxidase-linked, rabbit anti-goat IgG (Cappel) was developed according to the manufacturer's (Amersham) specifications. autoradiogram was exposed for <1 second. quantity of total recombinant α -trichosanthin in an extracted leaf sample was determined by comparing the crude extract autoradiogram signal to the signal obtained from known quantities of purified GLQ223. The ribosome inactivating activity was determined by measuring the inhibition of protein synthesis in a rabbit reticulocyte lysate system.

Confirmation of High Level Expression of Bilogically Active a-trichosanthin

The plant viral vector of the present invention directs the expression of α -trichosanthin in transfected plants. The open reading frame (ORF) for α -trichosanthin, from the genomic clone pQ21D (88), was placed under the control of the tobacco mosaic virus (TMV) coat protein subgenomic promoter.

Infectious RNA from pBGC 152 (Fig. 3) was prepared by in vitro transcription using SP6 DNA-dependent RNA polymerase and were used to mechanically inoculate N. benthamiana. The hybrid virus spread throughout all the non-inoculated upper leaves as verified by transmission electron microscopy (Fig. 4), local lesion infectivity assay, and polymerase chain reaction (PCR) amplification (20; data not shown). The 27 kDa a-trichosanthin accumulated in upper leaves (14 days post inoculation) to levels of at least 2% of total soluble protein and was analyzed by immunoblotting, using GLQ223 (78), a purified $\underline{\text{T.kirilowii}}$ derived α -trichosanthin, as a standard (Fig. 5A). No detectable cross-reacting protein was observed in the non-infected N. benthamiana control plant extracts (Fig. 5A, lane 5). Recombinant α -trichosanthin was easily detected in 7 μ g of crude leaf extract using a Coomassie stain (Fig. 5B, lane 3).

Prior investigators have reported a maximum accumulation of a foreign protein in any genetically engineered plant of 2% of the total soluble protein. Although the expression of potentially valuable proteins such as antibodies and human serum albumin has been reported previously (94,95) these were produced in Agrobacterium-mediated transgenic plants. A major difference between this plant viral expression system and previous methods is the quantity of protein produced and the amount of time required to obtain genetically engineered plants. Systemic infection and expression of α -trichosanthin occurred in less than two weeks while it takes several months to create a single transgenic plant.

The α -trichosanthin produced and purified from upper leaves in transfected N. benthamiana (14 days

post inoculation) was structurally identical to native a-trichosanthin. The 27 kDa protein crossreacted with anti- α -trichosanthin antibody and had an identical FPLC purification profile as the GLQ223 standard. Although the C-terminal sequence of the recombinant protein was not analyzed, both GLQ223 and the purified recombinant α-trichosanthin appeared to have identical electrophoretic mobilities (Fig. 5B). The exact C-terminal amino acid of the recombinant α trichosanthin remains to be determined. The Nterminal sequence, Asp-Val-Ser-Phe-Arg-Leu-Ser was obtained from the purified protein using an automated protein sequenator (96). This result indicated that the putative signal peptide of the preparation was correctly processed at the site indicated in Fig. 1. The removal of the putative signal peptide at this site was consistent with the statistical expectation by the method of von Heijne (97). It is possible that the a-trichosanthin signal peptide contributed to its high level expression by targeting the protein into the extracellular space. The nucleotide sequences surrounding the α -trichosanthin start codon might also have an effect on the efficiency of translation initiation.

It is interesting to note that nucleotides flanking the translation initiating sites of the highly expressed TMV-U1 (5' TTAAATATGTCT 3') and ORSV (5' TGAAATATGTCT 3') coat protein genes are conserved while the corresponding region in pBGC152/ α -trichosanthin (5' TCGAGGATGATC 3') shows very little similarity. It is possible that site directed mutagenesis of nucleotides near the translation initiation site of α -trichosanthin might increase its expression.

WO 93/03161 PCT/US92/06359

-84-

The recombinant α -trichosanthin caused a concentration dependent inhibition of protein synthesis in a cell-free rabbit reticulocyte translation assay (Fig. 6). The ID₅₀ (dosage required for 50% inhibition) was approximately .1 ng/ml, a value comparable to <u>T.kirilowii</u> derived α -trichosanthin (GLQ223). Based on the ID₅₀ and dose response, the enzyme produced in transfected plants had the same specific activity as the native protein. This result suggests that the fidelity of the viral RNA-dependent RNA polymerase was relatively high since base pair substitutions and deletions in the foreign sequence during viral amplification would lower the specific activity of the recombinant enzyme.

As the disclosed and claimed invention demonstrates, pBGC152 can direct the heterologous expression of biologically active α -trichosanthin in transfected plants. Large scale production of recombinant proteins can be easily obtained using the RNA viral-based system by simply increasing the size and number of inoculated plants. Since tissue containing high concentrations of α -trichosanthin can be harvested two weeks after inoculation this system can be used to rapidly screen the effects of site directed mutations. Identification of important amino acids involved in the inhibition of HIV replication in vivo may help to improve the efficacy of α -trichosanthin as a potential AIDS therapeutic drug.

The following plasmids have been deposited at the American Type Culture Collection (ATCC), Rockville, MD, USA, under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure and Regulations thereunder (Budapest Treaty) and are thus maintained and made available according to the terms of the Budapest Treaty. Availability of such plasmids is not to be construed as a license to practice the invention in contravention of the rights granted under the authority of any government in accordance with its patent laws.

The deposited cultures have been assigned the indicated ATCC deposit numbers:

<u>Plasmid</u>

ATCC No.

pTB2

75280

While the invention has been disclosed in this patent application by reference to the details of preferred embodiments of the invention, it is to be understood that this disclosure is intended in an illustrative rather than limiting sense, as it is contemplated that modifications will readily occur to those skilled in the art, within the spirit of the invention and the scope of the appended claims.

LISTING OF REFERENCES

- Grierson, D. et al., <u>Plant Molecular Biology</u>,
 Blackie, London, pp. 126-146 (1984).
- 2. Gluzman, Y. et al., <u>Communications in Molecular Biology: Viral Vectors</u>, Cold Spring Harbor Laboratory, New York, pp. 172-189 (1988).
- Ahlquist, P. and M. Janda, <u>Mol. Cell Biol.</u>
 4:2876 (1984)
- 4. Dawson, W.O. et al., <u>Proc. Nat. Acad. Sci. USA</u>
 83:1832 (1986).
- 5. Lebeurier, 6. et al., Gene 12:139 (1980).
- 6. Morinaga, T. et al. U.S. Patent No. 4,855,237.
- 7. Maniatis, T. et al., <u>Molecular Cloning</u> (1st Ed.) and Sambrook, J. et al. (2nd Ed.), Cold Spring Harbor Laboratory, Cold Spring Harbor (1982, 1989).
- 8. <u>Molecular Cloning</u>, D.M. Clover, Ed., IRL Press, Oxford (1985).
- 9. <u>Methods in Enzymology</u>, Vols. 68, 100, 101, 118 and 152-155 (1979, 1983, 1983, 1986 and 1987).
- 10. Brisson, N. et al., Methods in Enzymology 118:659 (1986).
- 11. Dawson, W.O. et al., <u>Virology</u> <u>172</u>:285-292 (1989).

- 12. Takamatsu, N. et al., <u>EMBO</u> <u>J</u> <u>6</u>:307-311 (1987).
- 13. French, R. et al., Science 231:1294-1297 (1986).
- 14. Takamatsu, N. et al., <u>FEBS Letters</u> <u>269</u>:73-76 (1990).
- 15. Miller, J.H., <u>Experiments in Molecular Genetics</u>, Cold Spring Harbor Laboratory, New York (1972).
- 16. <u>Virology</u> 132:71 (1984).
- 17. Deom, C.M. et al., Science 237:389 (1987).
- 18. Noru, Y. et al., <u>Virology</u> <u>45</u>:577 (1971).
- 19. Kurisu et al., <u>Virology</u> 70:214 (1976).
- 20. Fukuda, M. et al., <u>Proc. Nat. Acad. Sci. USA</u>
 <u>78</u>:4231 (1981).
- 21. Lebeurier, G. et al., <u>Proc. Nat. Acad. Sci. USA</u>
 74:1913 (1977).
- 22. Fukuda, M. et al., <u>Virology</u> 101:493 (1980).
- 23. Meshi, T. et al., <u>Virology</u> <u>127</u>:52 (1983).
- 24. Alquist et al., <u>J. Mol. Biol.</u> 153:23 (1981).
- 25. Hedgpeth, J.M. et al., <u>Mol. Gen. Genet.</u> <u>163</u>:197 (1978).
- 26. Bernard, H.M. et al., <u>Gene</u> <u>5</u>:59 (1979).

- Remaut, E.P. et al., Gene 15:81 (1981).
- Grimsley, N. et al., <u>Nature</u> <u>325</u>:177 (1987). 28.
- Gardner, R.C. et al., Plant Mol. Biol. 6:221 29. (1986).
- Grimsley, N. et al., Proc. Nat. Acad. Sci. USA 83:3282 (1986).
- 31. Lazarowitz, S.C., Nucl. Acids Res. 16:229 (1988).
- 32. Donson, J. et al., <u>Virology</u> 162:248 (1988).
- Hayes, R.J. et al., <u>J. Gen. Virol.</u> 69:891 33. (1988).
- 34. Elmer, J.S. et al., Plant Mol. Biol. 10:225 (1988).
- 35. Gardiner, W.E. et al., EMBO J 7:899 (1988).
- Huber, M. et al., <u>Biochemistry</u> 24, 6038 (1985). 36.
- Tanksley et al., Hort Science 23, 387 (1988). 37.
- Rao, et al., Journal of Heredity 74:34 (1983). 38.
- Dewey, et al., Cell 44:439-449 (1986). 39.
- 40. Pearson, O.N., Hort. Science 16:482 (1981).

- 41. Konvicha et al., Z. Pfanzenzychtung 80:265 (1978).
- 42. Remy et al., Theor. Appl. Genet. 64:249 (1983).
- 43. Padmaja et al. Cytologia 53:585 (1988).
- 44. Ebert et al., Cell 56:255 (1989).
- 45. Dawson, W.O. et al., <u>Phytopathology</u> 78:783 (1988).
- 46. Goelet, P. et al., <u>Proc. Nat. Acad. Sci. USA</u>
 79:5818 (1982).
- 47. Shaw, W.V., Meth. Enzymology 53:737 (1975).
- 47a. Logemann, J. et al., <u>Anal. Biochem.</u> <u>163</u>:16 (1987).
- 48. Ausubel, F.M. et al., <u>Current Protocols in Mol. Biol.</u>, Wiley, N.Y. (1987).
- 49. Zagursky, R. et al., <u>Gene Anal. Tech.</u> 2:89 (1985).
- 50. Goelet, P. an Karn, J., <u>J. Mol. Biol.</u> <u>154</u>:541 (1982).
- 51. Dougherty, W.G., <u>Virology</u> 131:473 (1983).
- 52. Kirkegaard, K. and Baltimore, D., <u>Cell</u> <u>47</u>:433 (1986).

- 53. Bujarski, J. and Kaesberg, P., <u>Nature</u> 321:528 (1986).
- 54. King, A.M.Q., in <u>RNA Genetics</u>, E. Domingo et al., Eds., Vol. II, 149-165, CRC Press, Inc., Boca Raton, Fla. (1988).
- 55. Keen, N.T. et al., Gene 70:191 (1988).
- 56. Beck, E. et al., Gene 19:327 (1982).
- 57. Brisson, N. et al., Nature 310:511 (1984).
- 58. Rogers, S.G. et al., <u>Plant Mol. Biol. Rep.</u>
 3:111 (1985).
- 59. Gooding Jr., G.V. and Herbert T.T., <u>Phytopathology</u> 57:1285 (1967).
- 60. Feinberg, A.P. and Vogelstein, B., Anal. Biochem. 137:266 (1984).
- 61. Bradford, M.M., Anal. Biochem. 72:248 (1976).
- 62. McDonnell, R.E. et al., <u>Plant Mol. Biol. Rep.</u> 5:380 (1987).
- 63. French, R. and Ahlquist, P., <u>J. Virol.</u> 62:2411 (1988).
- 64. Kurnagi, M.H. et al., Gene 94:209 (1990).
- 65. O'Neill, S.D. et al., <u>Mol. Gen. Genet.</u> <u>221</u>:235 (1990).

WO 93/03161 PCT/US92/06359

-91-

- Hanamoto, T. t al., Agric. Biol. Chem. 51:2019 66. (1987).
- 67. Henikoff, S., Gene 28:351 (1984).
- Nilsson et al., Nucl. Acids Res. 11:8019 (1983). 68.
- Gergan et al., Nucl. Acids Res. 7:2115 (1979). 69.
- 70. Higerd et al., <u>J. Bacteriol</u>. <u>114</u>:1184 (1973).
- 71. Ounissi, H. et al., Gene 35:271 (1985).
- 72. Ohashi, H. et al. Appl. Environ. Microbiol. <u>54</u>:2603 (1988).
- 73. Dewey, R.E. et al., Cell 44:439 (1986).
- 74. Wang, Y., Qian, R.-Q., Gu., Z.-W., Jin, S.-W., Zhang, L.-Q., Xia, Z.-X., Tian, G.-Y. & Ni, C.-Z. Pure appl. Chem. 58, 789-798 (1986).
- 75. Jimenez, A. & Vazquez D. Annu. Rev. Microbiol. 39, 649-672 (1985).
- Endo, Y., Mitsui, K., Motizuui, M. & Tsurugi, K 76. J. biol. Chem. 262, 5908-5912 (1987).
- 77. Maraganore, J. M., Joseph, M. & Bailey, M. C., J. biol. Chem. 262, 11628-11633 (1987).
- 78. Collins, E. J., Robertus, J. D., LoPresti, M., Stone, K. L., Williams, K. R., Wu, P., Hwang, & Piatak, M., J. biol. Ckem. 265, 8665-8669 . (1990).

- 79. McGrath., M. S., Hwang, K. M., Caldwell, S. E., Gaston, I., Luk, K.-C., Wu, P., Ng, V. L., Crowe, S., Daniels, J., Marsh, I., Dienhart, T., Lekas, P. V., Vennari, J. C., Yeung, H. J. & Lifson, D. Proc. natn. Acad. Sci. U.S.A. 86, 2844-2848 (1989).
- 80. Shaw, P.-C., Yung, M.-H., Zhu, R.-H., Ho, W. K.-K., Ng, T.-B. & Yeung, H.-W. Gene, 97, 267-272 (1991).
- 81. Ahlquist, P., French, R., Janda, M. & Loesch-Fries, S. Pròc. natn. Acad. Sci. U.S.A. 81, 7066-7070 (1984).
- 82. Miller, W. A., Dreher, T. W. & Hall, T. C.
 Nature 313, 68-70 (1985).
- 83. Takamatsu, N., Watanabe, Y., Yanagi, H., Meshi, T., Shiba, T. & Okada, Y. FEBS Lett. 269, 73-76 (1990).
- 84. Talcamatsu, N., Ishilcawa, M., Meshi, T. & Okada, Y. *EMBO J.* 6, 307-311 (1987).
- 85. Dawson, W. O., Lewandowski, D. J., Hilf, M. E., Bubrick, P., Raffo, A. J., Shaw, J. J., Grantham, G. L. & Desjardins, P. R. Virology 172, 285-292 (1989).
- 86. Donson, J., Kearney, C. M., Hilf, M. E. &
 Dawson, W. O. Proc. natn. Acad. Sci. U.S.A. 88,
 7204-7208 (1991).

WO 93/03161 PCT/US92/06359

- 87. Chow, T. P., Feldman, R. A., Lovett, M. & Piatak, M. J. biol. Chem. 265, 8670-8674 (1990).
- 88. Saiki, R. K., Scharf, S., Faloona, F., Mullis, K. B., Horn, G. T., Erlich, H. A. & Amheim, N. Science 230, 1350-1354 (1985).
- 89. Hiatt, A., Cafferkey, R. & Bowdish, K. *Nature* 342, 76-78 (1989).
- 90. Sijmons, P. C., Dekker, B. M. M., Schrammeijer, B., Verwoerd, T. C., van den Elzen, P. J. M.& Hoekema, A. Bio/Technology 8, 217-221 (1990).
- 91. Hewick, R. M., Hunkapiller, N. W., Hood, L. E. & Dreyer, W. J. J. biol. Chem. 256, 7990-7997 (1981).
- 92. von Heijne, G. Nucleic Acid Res. 14, 4683-4690 (1986).
- 93. Dawson, W. O., Beck, D. L., Knorr, D. A. Granthain, G. L. Proc. natn. Acad. Sci. U.S.A. 83, 1832-1836 (1986).
- 94. Laemmli, U. K. Nature 227, 680-685 (1970).
- 95. Bradford, M. M. Anal. Biochem. 72, 248-254 (1976).
- 96. Towbin, H., Staehelin, T., Gordon, J. Proc. Natl. Acad. Sci. U.S.A. 76, 4350-4354 (1979).
- 97. Piatak, et al., U.S. Patent No. 5,128,460 (1992).

SEQUENCE LISTING

- (1) GENERAL INFORMATION:
- (i) APPLICANT: Donson, Jon
 Dawson, William 0.
 Grantham, George L.
 Turpen, Thomas H.
 Turpen, Ann Myers
 Garger, Stephen J.
 Grill, Laurence K.
- (ii) TITLE OF INVENTION: RECOMBINANT PLANT VIRAL NUCLEIC ACIDS
- (iii) NUMBER OF SEQUENCES: 11
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Limbach & Limbach
 - (B) STREET: 2001 Ferry Building
 - (C) CITY: San Francisco
 - (D) STATE: CAL
 - (F) ZIP: 94111
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: Patent in Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 600,244
 - (B) FILING DATE: 22-OCT-1990
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 641,617
 - (B) FILING DATE: 16-JAN-1991
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 310,881
 - (B) FILING DATE: 17-FEB-1989
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 160,766
 - (B) FILING DATE: 26-FEB-1988
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 160,771
 - (B) FILING DATE: 26-FEB-1988

(vii)	PRIOR APPLICATION DATA:
	(A) APPLICATION NUMBER: US 347,637
	(B) FILING DATE: 05-MAY-1989
(vii)	PRIOR APPLICATION DATA:
(/	(A) APPLICATION NUMBER: US 363,138
	(B) FILING DATE: 08-JUN-1989
	(2)
(vii)	PRIOR APPLICATION DATA:
•	(A) APPLICATION NUMBER: US 219,279
	(B) FILING DATE: 15-JUL-1988
/	ATTORNEY/AGENT INFORMATION:
(viii)	ATTORNET/AGENT INFORMATION.
	(A) NAME: Halluin, Albert P.
	(B) REGISTRATION NUMBER: 28,957
	(C) REFERENCE/DOCKET NUMBER: BIOG-20121 USA
(ix)	TELECOMMUNICATION INFORMATION:
V 7	(A) TELEPHONE: 415-433-4150
	(B) TELEFAX: 415-433-8716
	(5)
403	THEADWANTON DAD CEO TO NO. 1.
(2)	INFORMATION FOR SEQ ID NO: 1:
(i)	SEQUENCE CHARACTERISTICS:
• •	(A) LENGTH: 4 amino acids
	(B) TYPE: amino acid
•	(D) TOPOLOGY: linear
	MOT TIOTT TI MUNUS manhida
(11)	MOLECULE TYPE: peptide
(iii)	HYPOTHETICAL: NO
(iv)	ANTI-SENSE: NO
(CRAHENOR DECORIDATION. CEO ID NO. 1.
(X1)	SEQUENCE DESCRIPTION: SEQ ID NO: 1:
Pro	Xaa Gly Pro
1	-
4-1	THEORY MAD AND AND TO NO. O.
(2)	INFORMATION FOR SEQ ID NO: 2:
(ĭ)	SEQUENCE CHARACTERISTICS:
\-,	(A) LENGTH: 13 base pairs
	(B) TYPE: nucleic acid
	(B) TYPE: nucleic acid (C) STRANDEDNESS: single
	(D) TOPOLOGY: linear
(ii)	MOLECULE TYPE: DNA (genomic)
(iii)	HYPOTHETICAL: NO

PCT/US92/06359 WO 93/03161

-96-

(iv)	ANTI-SENSE: NO										
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 2:										
GGGTACCTGG GCC 13											
(2)	INFORMATION FOR SEQ ID NO: 3:										
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 886 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear										
(ii)	MOLECULE TYPE: DNA (genomic)										
(iii)	HYPOTHETICAL: NO										
(iv)	ANTI-SENSE: NO										
(vi)	ORIGINAL SOURCE: (A) ORGANISM: Chinese cucumber										
vii)	<pre>IMMEDIATE SOURCE: (B) CLONE: alpha-trichosanthin</pre>										
(ix)	FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 8877 (B) LOCATION: 8877										
(xi)	SEQUENCE DESCRIPTION: SEQ ID NO: 3:										
CTCGAGG	ATG ATC AGA TTC TTA GTC CTC TCT TTG CTA ATT CTC ACC CTC49										
	Met Ile Arg Phe Leu Val Leu Ser Leu Leu Ile Leu Thr Leu 1 5 10										
TTC CTA	ACA ACT CCT GCT GTG GAG GGC GAT GTT AGC TTC CGT TTA TC#97										
Phe Leu 15	Thr Thr Pro Ala Val Glu Gly Asp Val Ser Phe Arg Leu Ser 20 25 30										
GGT GCA	ACA AGC AGT TCC TAT GGA GTT TTC ATT TCA AAT CTG AGA AAMS										
Gly Ala	Thr Ser Ser Ser Tyr Gly Val Phe Ile Ser Asn Leu Arg Lys										

GCT CTT CCA AAT GAA AGG AAA CTG TAC GAT ATC CCT CTG TTA CGT TCP3

Ala Leu Pro Asn Glu Arg Lys Leu Tyr Asp Ile Pro Leu Leu Arg Ser

			50					55					60		
TCT	CTT	CCA	GGT	TCT	CAA	CGC	TAC	GCA	TTG	ATC	CAT	CTC	ACA	AAT	TA224
Ser	Leu	Pro 65	Gly	Ser	Gln	Arg	Tyr 70	Ala	Leu	Ile	His	Leu 75	Thr	Asn	Tyr
GCC	GAT	GAA	ACC	ATT	TCA	GTG	GCC	ATA	GAC	GTA	ACG	AAC	GTC	TAT	A12189
Ala	Asp 08	Glu	Thr	Ile	Ser	Val 85	Ala	Ile	Asp	Val	Thr 90	Asn	Val	Tyr	Ile
ATG	GGA	TAT	CGC	GCT	GGC	GAT	ACA	TCC	TAT	TTT	TTC	AAC	GAG	GCT	TCE
Met 95	Gly	Tyr	Arg	Ala	Gly 100	Asp	Thr	Ser	Tyr	Phe 105	Phe	Asn	Glu	Ala	Ser 110
GCA	ACA	GAA	GCT	GCA	AAA	TAT	GTA	TTC	AAA	GAC	GCT	ATG	CGA	AAA	GIBS:
Ala	Thr	G1u	Ala	Ala 115	Lys	Tyr	Va1	Phe	Lys 120	Asp	"Ala	Met	Arg	Lys 125	Val
ACG	CTT	CCA	TAT	TCT	GGC	AAT	TAC	GAA	AGG	CTT	CAA	ACT	GCT	GCG	GCCC3
Thr	Leu	Pro	Tyr 130	Ser	Gly	Asn	Tyr	Glu 135	Arg	Leu	Gln	Thr	Ala 140	Ala	Gly
AAA	ATA	AGG	GAA	AAT	ATT	CCG	CTT	GGA	CTC	CCA	GCT	TTG	GAC	AGT	GCCC 1
Lys	Ile	Arg 145	Glu	Asn	Ile	Pro	Leu 150	Gly	Leu	Pro	Ala	Leu 155	Asp	Ser	Ala
ATT	ACC	act	TTG	TTT	TAC	TAC	AAC	GCC	AAT	TCT	GCT	GCG	TCG	GCA	C'5129
Ile	Thr 160	Thr	Leu	Phe	Tyr	Tyr' 165	Asn	Ala	Asn	Ser	Ala 170	Ala	Ser	Ala	Leu
ATG	GTA	CTC	ATT	CAG	TCG	ACG	TCT	GAG	GCT	GCG	AGG	TAT	AAA _	TTT	A75077
Met 175	Val	Leu	Ile	Gln	Ser 180	Thr	Ser	Glu	Ala 185	Ala	Arg	Tyr	Lys	Phe	11e 190
GAG	CAA	CAA	ATT	GGG	AAG	CGC	GTT	GAC	AAA	ACC	TTC	CTA	CCA	AGT	T 162 5
Glu	Gln	Gln	Ile	Gly 195	Lys	Arg	Val	Asp	Lys 200	Thr	Phe	Leu	Pro	Ser 205	Leu
GCA	TTA	ATA	AGT	TTG	GAA	TAA	AGT	TGG	TCT	GCT	CTC	TCC	AAG	CAA	ATET 3
Ala	Ile	Ile	ser 210	Leu	Glu	Asn	Ser	Trp 215	Ser	Ala	Leu	Ser	Lys 220	Gln	Ile

WO 93/03161 PCT/US92/06359

-98-

CAG ATA GCG AGT ACT AAT AAT GGA CAG TTT GAA ACT CCT GTT GTG CEWE1

Gln Ile Ala Ser Thr Asn Asn Gly Gln Phe Glu Thr Pro Val Val Leu
225 CAA AAC CAA CGA GTC ATG ATA ACC AAT GTT GAT GCT GCM69

Ile Asn Ala Gln Asn Gln Arg Val Met Ile Thr Asn Val Asp Ala Gly
240 CTC AAC ATC GCG TTG CTG CTG AAT CGA AAC AAT ATG GCM7

Val Val Thr Ser Asn Ile Ala Leu Leu Leu Asn Arg Asn Asn Met Ala
255 CAT GAT GAC GAT GTT CCT ATG ACA CAG AGC TTT GGA TGT GGA ACC
ALC ATG GAT GAC GAT GTT CCT ATG ACA CAG AGC TTT GGA TGT GGA ACC
ALC ALC ASP Asp Asp Val Pro Met Thr Gln Ser Phe Gly Cys Gly Ser

TAT GCT ATT TAGTAACTCG AG

886

Tyr Ala Ile

290

- (2) INFORMATION FOR SEQ ID NO:4:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 289 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met lIe Arg Phe Leu Val Leu Ser Leu Leu Ile Leu Thr Leu Phe Leu

1 10 15

Thr Thr Pro Ala Val Glu Gly Asp Val Ser Phe Arg Leu Ser Gly Ala
20 25 30

Thr Ser Ser Ser Tyr Gly Val Phe Ile Ser Asn Leu Arg Lys Ala Leu 35 40 45

Pro Asn Glu Arg Lys Leu Tyr Asp Ile Pro Leu Leu Arg Ser Ser Leu 50 55 60 .

Pro Gly Ser Gln Arg Tyr Ala Leu Ile His Leu Thr Asn Tyr Ala Asp 65 70 75 80 Glu Thr Ile Ser Val Ala Ile Asp Val Thr Asn Val Tyr Ile Met Gly
85 90 95

Tyr Arg Ala Gly Asp Thr Ser Tyr Phe Phe Asn Glu Ala Ser Ala Thr 100 105 110

Glu Ala Ala Lys Tyr Val Phe Lys Asp Ala Met Arg Lys Val Thr Leu 115 120 125

Pro Tyr Ser Gly Asn Tyr Glu Arg Leu Gln Thr Ala Ala Gly Lys Ile 130 135 140

Arg Glu Asn Ile Pro Leu Gly Leu Pro Ala Leu Asp Ser Ala Ile Thr 145 150 155 160

Thr Leu Phe Tyr Tyr Asn Ala Asn Ser Ala Ala Ser Ala Leu Met Val 165 170 175

Leu Ile Gln Ser Thr Ser Glu Ala Ala Arg Tyr Lys Phe Ile Glu Gln 180 185 190

Gln Ile Gly Lys Arg Val Asp Lys Thr Phe Leu Pro Ser Leu Ala Ile 195 200 205

The Ser Leu Glu Asn Ser Trp Ser Ala Leu Ser Lys Gln He Gln He 210 215 220

Ala Ser Thr Asn Asn Gly Gln Phe Glu Thr Pro Val Val Leu Ile Asn 225 230 235 240

Ala Gln Asn Gln Arg Val Met Ile Thr Asn Val Asp Ala Gly Val Val 245 250 255

Thr Ser Asn Ile Ala Leu Leu Leu Asn Arg Asn Asn Met Ala Ala Met 260 265 270

Asp Asp Val Pro Met Thr Gln Ser Phe Gly Cys Gly Ser Tyr Ala 275 280 285

Ile

- (2) INFORMATION FOR SEQ ID NO: 5:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1452 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)

- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 (A) ORGANISM: Oryza sativa
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: alpha-amylase
- (ix) FEATURE:
 - (A) NAME/KEY: CDS (B) LOCATION: 12. .1316
 - (B) LOCATION: 12. .1316
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CCTCGAGGTG C ATG CAG GTG CTG AAC ACC ATG GTG AAC A CAC TTC TTG 50

Met Gln Val Leu Asn Thr Met Val Asn Lys His Phe Leu
1 5 10

TCC CTT TCG GTC CTC ATC GTC CTC CTT GGC CTC TCC TCC AAC TTG AC#8

Ser Leu Ser Val Leu Ile Val Leu Gly Leu Ser Ser Asn Leu Thr
15 20 25

GCC GGG CAA GTC CTG TTT CAG GGA TTC AAC TGG GAG TCG TGG AAG GAMA6

Ala Gly Gln Val Leu Phe Gln Gly Phe Asn Trp Glu Ser Trp Lys Glu 30 35 40 45

AAT GGC GGG TGG TAC AAC TTC CTG ATG GGC AAG GTG GAC GAC ATC GCC94

Asn Gly Gly Trp Tyr Asn Phe Leu Met Gly Lys Val Asp Asp Ile Ala 50 55 60

GCA GCC GGC ATC ACC CAC GTC TGG CTC CCT CCG CCG TCT CAC TCT GTM42

Ala Ala Gly Ile Thr His Val Trp Leu Pro Pro Pro Ser His Ser Val 65 70 75

GGC GAG CAA GGC TAC ATG CCT GGG CGG CTG TAC GAT CTG GAC GCG TC290

Gly Glu Gln Gly Tyr Met Pro Gly Arg Leu Tyr Asp Leu Asp Ala Ser 80 85 90

AAG TAC GGC AAC GAG GCG CAG CTC AAG TCG CTG ATC GAG GCG TTC CRES

Lys Tyr Gly Asn Glu Ala Gln Leu Lys Ser Leu Ile Glu Ala Phe His
95 100 105

GGC AAG GGC GTC CAG GTG ATC GCC GAC ATC GTC ATC AAC CAC CGC ACEB6 Gly Lys Gly Val Gln Val Ile Ala Asp Ile Val Ile Asn His Arg Thr 110 GCG GAG CAC AAG GAC GGC CGC GGC ATC TAC TGC CTC TTC GAG GGC GGC34 Ala Glu His Lys Asp Gly Arg Gly Ile Tyr Cys Leu Phe Glu Gly Gly 130 135 ACG CCC GAC TCC CGC CTC GAC TGG GGC CCG CAC ATG ATC TGC CGC GATB2 Thr Pro Asp Ser Arg Leu Asp Trp Gly Pro His Met Ile Cys Arg Asp 145 GAC CCC TAC GGC CAT GGC ACC GGC AAC CCG GAC ACC GGC GCC GAC TEED Asp Pro Tyr Gly Asp Gly Thr Gly Asn Pro Asp Thr Gly Ala Asp Phe 160 GCC GCC GCG CCG GAC ATC GAC CAC CTC AAC AAG CGC GTC CAG CGG GREEB Ala Ala Ala Pro Asp Ile Asp His Leu Asn Lys Arg Val Gln Arg Glu CTC ATT GGC TGG CTC GAC TGG CTC AAG ATG GAC ATC GGC TTC GAC GGE26 Leu Ile Gly Trp Leu Asp Trp Leu Lys Met Asp Ile Gly Phe Asp Ala 190 195 200 TGG CGC CTC GAC TTC GCC AAG GGC TAC TCC GCC GAC ATG GCA AAC ATE 4 Trp Arg Leu Asp Phe Ala Lys Gly Tyr Ser Ala Asp Met Ala Lys Ile TAC ATC GAC GCC ACC GAG CCG AGC TTC GCC GTG CCC GAG ATA TCG ACC22 Tyr Ile Asp Ala Thr Glu Pro Ser Phe Ala Val Ala Glu Ile Trp Thr 225 230 TCC ATG GCG AAC GGC GGG GAC GGC AAG CCG AAC TAC GAC CAG AAC GCCFO Ser Met Ala Asn Gly Gly Asp Gly Lys Pro Asn Tyr Asp Gln Asn Ala 245 CAC CGG CAG GAG CTG GTC AAC TGG GTC GAT CGT GTC GGC GGC GCC ARCL8 His Arg Gln Glu Leu Val Asn Trp Val Asp Arg Val Gly Ala Asn 255 260 265 ACC AAC GGC ACG GCG TTC GAC TTC ACC ACC AAG GGC ATC CTC AAC GTEB6

Ser Asn Gly Thr Ala Phe Asp Phe Thr Thr Lys Gly Ile Leu Asn Val GCC GTG GAG GGC GAG CTG TGG CGC CTC CGC GGC GAG GAC GGC AAG GC914 Ala Val Glu Gly Glu Leu Trp Arg Leu Arg Gly Glu Asp Gly Lys Ala 290 CCC GGC ATG ATC GGG TGC TGG CCG GCC AAG GCG ACG ACC TTC GTC GREE2 Pro Gly Met Ile Gly Trp Trp Pro Ala Lys Ala Thr Thr Phe Val Asp 310 AAC CAC GAC ACC GGC TCG ACG CAC CTG TGG CCG TTC CCC TCC GATLO Asn His Asp Thr Gly Ser Thr Gln His Leu Trp Pro Phe Pro Ser Asp 320 325 330 · AAG GTC ATG CAG GGC TAC GCA TAC ATC CTC ACC CAC CCC GGC AAC CCC58 Lys Val Met Gln Gly Tyr Ala Tyr Ile Leu Thr His Pro Gly Asn Pro TGC ATC TTG TAC GAC CAT TTC TTC GAT TGG GGT CTC AAG GAG GAG ATMO6 Cys Ile Phe Tyr Asp His Phe Phe Asp Trp Gly Leu Lys Glu Glu Ile · 355 360 350 GAG CGC CTG GTG TCA ATC AGA AAC CGG CAG GGG ATC CAC CCG GCG ACC54 Glu Arg Leu Val Ser Ile Arg Asn Arg Gln Gly Ile His Pro Ala Ser GAG CTG CGC ATC ATG GAA GCT GAC AGC GAT CTC TAC CTC GCG GAG ANDO2 Glu Leu Arg Ile Met Glu Ala Asp Ser Asp Leu Tyr Leu Ala Glu Ile 385 390 GAT GGC AAG GTG ATC ACA AAG ATT GGA CCA AGA TAC GAC GTC GAA CP250 Asp Gly Lys Val Ile Thr Lys Ile Gly Pro Arg Tyr Asp Val Glu His 400 405 CTC ATC CCC GAA GGC TTC CAG GTC GTC GCG CAC GGT GAT GGC TAC GC298 Leu Ile Pro Glu Gly Phe Gln Val Val Ala His Gly Asp Gly Tyr Ala ATC TGG GAG AAA ATC TGAGCGCACG ATGACGAGAC TCTCAGTTTA GCAGATTTAE3 Ile Trp Glu Lys LIe 430 435

-103-

	CCTGCGATTT TTACCCTGAC CGGTATACGT ATATACGTGC CGGCAACGAG CTGTATCCGA											1413			
TCCGAATTAC GGATGCAATT GTCCACGAAG TCCTCGAGG												1452			
(2) INFORMATION FOR SEQ ID NO: 6:															
(i)	SEQUENCE CHARACTERISTICS: (A) LENGTH: 434 amino acids (B) TYPE: amino acid (D) Topology: linear														
(ii)	ii) MOLECULE TYPE: protein														
(xi)		S	EQUE	ince	DE	SCR1	PTI	ON:	SEÇ] ID	NO	6:			
Met 1	Gln	Val	Leu	Asn 5	Thr	Met	Val	Asn	Lys 10	His	Phe	Leu	Ser	Leu 15	ser
Val	Leu	Ile	Val 20	Leu	Leu	Gly	Leu	Ser 25	Ser	Asn	Leu	Thr	Ala 30	Gly	Gln
Val	Leu	Phe 35	Gln	Gly	Phe	Asn	Trp 40	Glu	Ser	Trp	Lys	Glu 45	Asn	Gly	Gly
Trp	Tyr 50	Asn	Phe	Leu	Met	Gly 55	Lys	Val	Asp	Asp	Ile 60	Ala	Ala	Ala	Gly
Ile 65	Thr	His	Val	Trp	Leu 70	Pro	Pro	Pro	ser	His 75	Ser	Val	Gly	Glu	Gln 80
Gly	Tyr	Met	Pro	Gly 85	Arg	Leu	Tyr	Asp	Leu 90	Asp	Ala	Ser	Lys	Tyr 95	Gly
Aøn.	Glu	Ala	Gln 100	Leu	Lys	Ser	Leu	Ile 105	Glu	Ala	Phe	His	Gly 110	Lys	Gly
Val	Gln	Val 115	Ile	Ala	Asp	Ile	Val 120	Ile	Asn	His	Arg	Thr 125	Ala	Glu	His
Lys	Asp 130	Gly	Arg	Gly	Ile	Tyr 135	Сув	Leu	Phe	Glu	Gly 140	Gly	Thr	Pro	Asp
Ser 145	Arg	Leu	Asp	Trp	Gly 150	Pro	His	Met	Ile	Cys 155	Arg	Asp	Asp	Pro	T yr 160
Gly	Asp	Gly	Thr	Gly 165	Asn	Pro	Asp	Thr	Gly 170	Ala	Asp	Phe	Ala	Ala 175	Ala

- Pro Asp Ile Asp His Leu Asn Lys Arg Val Gln Arg Glu Leu Ile Gly 180 185 190
- Trp Leu Asp Trp Leu Lys Met Asp Ile Gly Phe Asp Ala Trp Arg Leu 195 200 205
- Asp Phe Ala Lys Gly Tyr Ser Ala Asp Met Ala Lys Ile Tyr Ile Asp 210 215 220
- Ala Thr Glu Pro Ser Phe Ala Val Ala Glu Ile Trp Thr Ser Met Ala 225 230 235 240
- Asn Gly Gly Asp Gly Lys Pro Asn Tyr Asp Gln Asn Ala His Arg Gln 245 250 255
- Glu Leu Val Asn Trp Val Asp Arg Val Gly Gly Ala Asn Ser Asn Gly
 260 265 270
- Thr Ala Phe Asp Phe Thr Thr Lys Gly Ile Leu Asn Val Ala Val Glu 275 280 285
- Gly Glu Leu Trp Arg Leu Arg Gly Glu Asp Gly Lys Ala Pro Gly Met 290 295 300
- Ile Gly Trp Trp Pro Ala Lys Ala Thr Thr Phe Val Asp Asn His Asp 305 310 315 320
- Thr Gly Ser Thr Gln His Leu Trp Pro Phe Pro Ser Asp Lys Val Met 325 330 335
- Gln Gly Tyr Ala Tyr Ile Leu Thr His Pro Gly Asn Pro Cys Ile Phe 340 345 350
- Tyr Asp His Phe Phe Asp Trp Gly Leu Lys Glu Glu Ile Glu Arg Leu 355 360 365
- Val Ser Ile Arg Asn Arg Gln Gly Ile His Pro Ala Ser Glu Leu Arg 370 375 380
- Ile Met Glu Ala Asp Ser Asp Leu Tyr Leu Ala Glu Ile Asp Gly Lys
- Val Ile Thr Lys Ile Gly Pro Arg Tyr Asp Val Glu His Leu Ile Pro 405 410 415
- Glu Gly Phe Gln Val Val Ala His Gly Asp Gly Tyr Ala Ile Trp Glu 420 425 430

Lys Ile

(2) INFORMATION FOR SEQ ID NO:7:	
(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 709 base pairs (B) TYPE: nucleic acid (G) STRANDEDNESS: single (D) TOPOLOGY: linear	
(ii) MOLECULE TYPE: cDNA to mRNA	
(iii) HYPOTHETICAL: NO	
(iv) ANTI-SENSE: NO	
<pre>(vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens</pre>	
<pre>(vii)</pre>	
(ix) FEATURE: (A) NAME/KEY: transit_peptide (B) LOCAT 26241 (B) LOCATION: 26241	· ·ION:
(ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 245670	
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:	
CTCGAGGGCA TCTGATCTTT CAAGAATGGC ACAAATTAAC AACATGGCAC AAGGGATACA	6
AACCCTTAAT CCCAATTCCA ATTTCCATAA ACCCCAAGTT CCTAAATCTT	12
TGTTTTTGGA TGTAAAAAAC TGAAAATTC AGCAAATTCT ATGTTGGTTT TGAI	EX RAAA
TTCAATTTTT ATGCAAAAGT TTTGTTCCTT TAGGATTTCA GCAGGTGGTA GAGTTTCTTG	24
CATG GTG CTG TCT CCT GCC GAC AAG ACC AAC GTC AAG GCC GCC	IGG GGG 28
Val Leu Ser Pro Ala Asp Lys Thr Asn Val Lys Ala Ala ?	Frp Cly
AAG GTT GGC GCG CAC GCT GGC GAG TAT GGT GCG GAG GCC CTG GA	ag aggs
Lys Val Gly Ala His Ala Gly Glu Tyr Gly Ala Glu Ala Leu G	lu Arg

ATG TTC CTG TCC TTC CCC ACC ACC AAG ACC TAC TTC CCG CAC TTC GRES Met Phe Leu Ser Phe Pro Thr Thr Lys Thr Tyr Phe Pro His Phe Asp 40 35 CTG AGC CAC GGC TCT GCC CAG GTT AAG GGC CAC GGC AAG AAG GTG GCC33 Leu Ser His Gly Ser Ala Gln Val Lys Gly His Gly Lys Lys Val Ala 55 GAC GOG CTG ACC AAC GCC GTG GCG CAC GTG GAC GAC ATG CCC AAC GCCB1 Asp Ala Leu Thr Asn Ala Val Ala His Val Asp Asp Met Pro Asn Ala 70 65 CTG TCC GCC CTG AGC GAC CTG CAC GCG CAC AAG CTT CGG GTG GAC CCE29 Leu Ser Ala Leu Ser Asp Leu His Ala His Lys Leu Arg Val Asp Pro 85 GTC AAC TTC AAG CTC CTA AGC CAC TGC CTG CTG GTG ACC CTG GCC GCC7 Val Asn Phe Lys Leu Leu Ser His Cys Leu Leu Val Thr Leu Ala Ala CAC CTC CCC GCC GAG TTC ACC CCT GCG GTG CAC GCC TCC CTG GAC ARE25 His Leu Pro Ala Glu Phe Thr Pro Ala Val His Ala Ser Leu Asp Lys 120 115 TTC CTG GCT TCT GTG AGC ACC GTG CTG ACC TCC AAA TAC CGT 677 TAAGCTGGAG Phe Leu Ala Ser Val Ser Thr Val Leu Thr Ser Lys Tyr Arg 135 140 130

CCTCGGTAGC CGTTCCTCCT GCCCGGTCGA CC

- (2) INFORMATION FOR SEQ ID NO:8:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 141 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (ix) SEQUENCE DESCRIPTION: SEQ ID NO:8:

- Val Leu Ser Pro Ala Asp Lys Thr Asn Val Lys Ala Ala Trp Gly Lys 10
- Val Gly Ala His Ala Gly Glu Tyr Gly Ala Glu Ala Leu Glu Arg Met
- Phe Leu Ser Phe Pro Thr Thr Lys Thr Tyr Phe Pro His Phe Asp Leu
- Ser His Gly Ser Ala Gln Val Lys Gly His Gly Lys Lys Val Ala Asp 55
- Ala Leu Thr Asn Ala Val Ala His Val Asp Asp Met Pro Asn Ala Leu 75
- Ser Ala Leu Ser Asp Leu His Ala His Lys Leu Arg Val Asp Pro Val 90
- Asn Phe Lys Leu Leu Ser His Cys Leu Leu Val Thr Leu Ala Ala His 100 105
- Leu Pro Ala Glu Phe Thr Pro Ala Val His Ala Ser Leu Asp Lys Phe 120
- Leu Ala Ser Val Ser Thr Val Leu Thr Ser Lys Tyr Arg 130 135
- (2) INFORMATION FOR SEQ ID NO:9:
- SEQUENCE CHARACTERISTICS: (i)
 - (A) LENGTH: 743 base pairs(B) TYPE: nucleic acid

 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iii) HYPOTHETICAL: NO
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE: (B) CLONE: beta-hemoglobin
- (ix) FEATURE: (A) NAME/KEY: transit_peptide (B) LOCATION: 26. .241

-108-

	(B) LOCA	ATION: 26.	.241				
(ix)	` '	E/KEY: CDS ATION: 245					
(xi)	SEQUENCE	DESCRIPTI	ON: SEQ ID	NO: 9:			
CTCGAGGGGA TCTGATCTTT CAAGAATGGC ACAAATTAAC AACATGGCAC AAGGGATACA 60							
AACCCTTAAT CAAGTTTTCT		A ATTTCCATA	A ACCCCAAGTT	CCTAAATCTT 120			
TGTTTTTGGA TCTAAAAAAC TGAAAAATTC AGCAAATTCT ATGTTGGTTT TGAAAAAAAGA 180							
TTCAATTTT ATGCAAAAGT TTTGTTCCTT TAGGATTTCA GCAGGTGGTA GAGTTTCTTG 240							
GATG GTG CAC CTG ACT CCT GAG GAG AAG TCT GCC GTT ACT GCC CTG TGG 289							
Val H	is Leu Thr	Pro Glu Glu 5	ı Lys Ser Ala 10	Val Thr Ala Leu Trp			
GGC AAG GT	G AAC GTG	GAT GAA GTT	GGT GGT GAG	GCC CTG GGC AGG CTG37			
Gly Lys Va	l Asn Val 2 20	Asp Glu Val	Gly Gly Glu 25	Ala Leu Gly Arg Leu 30			
CTG GTG GT	C TAC CCT	TGG ACC CAG	AGG TTC TTT	GAG TCC TTT GGG GAMB5			
Leu Val Va	I Tyr Pro ! 35	Trp Thr Gln	Arg Phe Phe 40	Glu Ser Phe Gly Asp 45			
CTG TCC AC	T CCT GAT	GCT GTT ATG	GGC AAC CCT	AAG GTG AAG GCT CATS3			
	r Pro Asp 1	Ala Val Met 55	Gly Asn Pro	Lys Val Lys Ala His 60			
GGC AAG AA	A GTG CTG (GGT GCC TTT	AGT GAT GGC	CTG GCT CAC CTG GAMB1			
Gly Lys Ly 65	s Val Leu (Gly Ala Phe 70	Ser Asp Gly	Leu Ala His Leu Asp 75			
AAC CTC AA	g ggc acc 1	ITT GCC ACCA	CTG AGT GAG	CTG CAC TGT GAC AAG 529			
Asn Leu Ly 80	s Gly Thr I	Phe Ala Thr 85	Leu Ser Glu 90	Leu His Cys Asp Lys 95			

743

-109-

CTG CAC GTG GAT CCT GAG AGC TTC AGG CTC CTA GGC AAC GTG CTG GEO7 Leu His Val Asp Pro Glu Ser Phe Arg Leu Leu Gly Asn Val Leu Val 100 105 TGT GTG CTG GCG CAT CAC TTT GGC AAA GAA TTC ACC CCA CCA GTG CR25 Cys Val Leu Ala His His Phe Gly Lys Glu Phe Thr Pro Pro Val Gln 115 GCT GCC TAT CAG AAA GTG GTG GCT GGT GTG GCT AAT GCC CTG GCC CACY3 Ala Ala Tyr Gln Lys Val Val Ala Gly Val Ala Asn Ala Leu Ala His AAG TAT CAC TAAGCTCGCT TTCTTGCTGT CCAATTTCTA TTAAAGGTTC 722 Lys Tyr His 145 CTTTGTGGGG TCGAGGTCGA C

- (2) INFORMATION FOR SEQ ID NO: 10:
- (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 146 amino acids
 - (B) TYPE: amino acid
- (D) TOPOLOGY: linear
- MOLECULE TYPE: protein (ii)
- SEQUENCE DESCRIPTION: SEQ ID NO: 10: (xi)

Val His Leu Thr Pro Glu Glu Lys Ser Ala Val Thr Ala Leu Trp Gly

Lys Val Asn Val Asp Glu Val Gly Glu Ala Leu Gly Arg Leu Leu

Val Val Tyr Pro Trp Thr Gln Arg Phe Phe Glu Ser Phe Gly Asp Leu

Ser Thr Pro Asp Ala Val Met Gly Asn Pro Lys Val Lys Ala His Gly

Lys Lys Val Leu Gly Ala Phe Ser Asp Gly Leu Ala His Leu Asp Asn

Leu Lys Gly Thr Phe Ala Thr Leu Ser Glu Leu His Cys Asp Lys Leu 85

PCT/US92/06359

-110-

His Val Asp Pro Glu Ser Phe Arg Leu Leu Gly Asn Val Leu Val Cys 100 105 110

Val Leu Ala His His Phe Gly Lys Glu Phe Thr Pro Pro Val Gln Ala 115 120 125

Ala Tyr Gln Lys Val Val Ala Gly Val Ala Asn Ala Leu Ala His Lys 130 135 140

Tyr His 145

- (2) INFORMATION FOR SEQ ID NO:11:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 17 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: N-terminal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: alkalophilic Bacillus sp.
 - (B) STRAIN: 38-2
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: beta-cyclodextrin
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: I1:

. Ala Pro Asp Thr Ser Val Ser Asn Lys Gln Asn Phe Ser Thr Asp Val 1 5 10 15

Ile

WHAT IS CLAIMED IS:

- 1. A recombinant plant viral nucleic acid comprising a native plant viral subgenomic promoter, at least one non-native plant viral subgenomic promoter and a plant viral coat protein coding sequence, wherein said non-native plant viral subgenomic promoter is capable of initiating transcription of an adjacent nucleic acid sequence in a host plant and is incapable of recombination with the recombinant plant viral nucleic acid subgenomic promoters and said recombinant plant viral nucleic acid is capable of systemic infection in a host plant.
- 2. The recombinant plant viral nucleic acid of claim 1 which further comprises at least one non-native nucleic acid sequence adjacent a subgenomic promoter, said sequence capable of transcription in a host plant to produce a cellular product.
- 3. The recombinant plant viral nucleic acid of claim 1 wherein the plant viral coat protein coding sequence is adjacent one non-native plant viral subgenomic promoter.
- 4. The recombinant plant viral nucleic acid of claim 3 wherein said plant viral coat protein coding sequence is a non-native coding sequence.
- 5. The recombinant plant viral nucleic acid of claim 3 wherein said plant viral coat protein coding sequence is a native coding sequence.
- The recombinant plant viral nucleic acid of claim
 wherein the plant viral coat protein coding

sequence is adjacent said native plant viral subgenomic promoter.

- 7. The recombinant plant viral nucleic acid of claim 6 wherein said plant viral coat protein coding sequence is a non-native coding sequence.
- 8. The recombinant plant viral nucleic acid of claim 6 wherein said plant viral coat protein coding sequence is a native coding sequence.
- 9. The recombinant plant viral nucleic acid of claim 2 wherein the plant viral coat protein coding sequence is adjacent one non-native plant viral subgenomic promoter.
- 10. The recombinant plant viral nucleic acid of claim 9 wherein said plant viral coat protein coding sequence is a non-native coding sequence.
- 11. The recombinant plant viral nucleic acid of claim 9 wherein said plant viral coat protein coding sequence is a native coding sequence.
- 12. The recombinant plant viral nucleic acid of claim 2 wherein the plant viral coat protein coding sequence is adjacent said native plant viral subgenomic promoter.
- 13. The recombinant plant viral nucleic acid of claim 12 wherein said plant viral coat protein coding sequence is a non-native coding sequence.

- 14. The recombinant plant viral nucleic acid of claim 12 wherein said plant viral coat protein coding sequence is a native coding sequence.
- 15. The recombinant plant viral nucleic acid of claim 9 wherein one non-native nucleic acid sequence is adjacent said native plant viral subgenomic promoter.
- 16. The recombinant plant viral nucleic acid of claim 10 wherein one non-native nucleic acid sequence is adjacent said native plant viral subgenomic promoter.
- 17. The recombinant plant viral nucleic acid of claim 11 wherein one non-native nucleic acid sequence is adjacent said native plant viral subgenomic promoter.
- 18. A recombinant plant viral nucleic acid comprising a native plant viral subgenomic promoter, at least one non-native plant viral subgenomic promoter, a plant viral coat protein coding sequence, and at least one non-native nucleic acid sequence, wherein said non-native plant viral subgenomic promoter is capable of initiating transcription of an adjacent nucleic acid sequence in a host plant and is incapable of recombination with the recombinant plant viral nucleic acid subgenomic promoters, said recombinant plant viral nucleic acid is capable of systemic infection in a host plant, said plant viral coat protein coding sequence is selected from the group consisting of a native plant viral coat protein coding sequence and a non-native plant viral coat protein c ding sequence, and said plant viral coat

protein coding sequence is adjacent one of the recombinant plant viral nucleic acid subgenomic promoters and said non-native nucleic acid sequence is adjacent one of the other plant viral subgenomic promoter.

- 19. The recombinant plant viral nucleic acid of claim 18 wherein the plant viral coat protein coding sequence is adjacent one non-native plant viral subgenomic promoter.
- 20. The recombinant plant viral nucleic acid of claim 19 wherein said plant viral coat protein coding sequence is a non-native coding sequence.
- 21. The recombinant plant viral nucleic acid of claim 19 wherein said plant viral coat protein coding sequence is a native coding sequence.
- 22. The recombinant plant viral nucleic acid of claim 18 wherein the plant viral coat protein coding sequence is adjacent said native plant viral subgenomic promoter.
- 23. The recombinant plant viral nucleic acid of claim 22 wherein said plant viral coat protein coding sequence is a non-native coding sequence.
- 24. The recombinant plant viral nucleic acid of claim 22 wherein said plant viral coat protein coding sequence is a native coding sequence.
- 25. The recombinant plant viral nucleic acid of claim 18 which comprises two or more non-native plant viral subgenomic promoters.


- 26. The recombinant plant viral nucleic acid of claim 25 which comprises two or more non-native nucleic acid sequence adjacent subgenomic promoters.
- 27. A host plant infected by the recombinant plant viral nucleic acid of claim 2.
- 28. A host plant infected by the recombinant plant viral nucleic acid of claim 9.
- 29. A host plant infected by the recombinant plant viral nucleic acid of claim 12.
- 30. A host plant infected by the recombinant plant viral nucleic acid of claim 18.
- 31. A host plant infected by the recombinant plant viral nucleic acid of claim 19.
- 32. A host plant infected by the recombinant plant viral nucleic acid of claim 22.
- 33. A host plant infected by the recombinant plant viral nucleic acid of claim 26.
- 34. A process for producing a product in a host plant which comprises infecting a host plant with the recombinant plant viral nucleic acid of claim 2, and growing said infected plant for the production of said product.
- 35. The process of claim 34 which further comprises isolation of the product.

- 36. A process for producing a product in a host plant which comprises infecting a host plant with the recombinant plant viral nucleic acid of claim 18, and growing said infected plant for the production of said product.
- 37. The process of claim 36 which further comprises isolation of the product.
- 38. A process for producing a product in a host plant which comprises infecting a host plant with the recombinant plant viral nucleic acid of claim 26, and growing said infected plant for the production of said product.
- 39. The process of claim 38 which further comprises isolation of the product.
- 40. The process of claim 38 wherein said product is a biologically active polypeptide or protein.
- 41. The process of claim 40 wherein said product is selected from the group consisting of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, EPO, G-CSF, GM-CSF, hPG-CSF, M-CSF, Factor VIII, Factor IX, tPA, hGH, receptors, receptor antagonists, antibodies, neuro-polypeptides, melanin, insulin, vaccines and the like.
- 42. The process of claim 38 wherein said product is biologically inactive polypeptide or protein resulting from anti-sense RNA expression.

WO 93/03161 PCT/US92/06359

-117-

- 43. A biologically functional plasmid or viral DNA vector having the characteristics of TB2 (ATCC No. 75280) and mutants thereof.
- 44. A biologically functional plasmid or viral DNA vector having the characteristics of TBU5 and mutants thereof.






Figure 2

"Western" analyses: Proteins were separated on polyacrylamide gels and then probed with antibodies specific for Trichosanthin.




Figure 3

4/8



Figure 4

1 2 3 4 5 6

-- <27 kDa</p>

Figure 5a

6 / 8




Figure 5b





Figure 6



04/11/2003, EAST Version: 1.03.0002

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/06359

A. CLASSIFICATION OF SUBJECT MATTER IPC(5): IPC(5): C12N 15/83; C12P 21/02							
US CL: US CL: 435/69.1, 320.1							
According to International Patent Classification (IPC) or to both national classification and IPC							
B. FIELDS SEARCHED							
Minimum documentation searched (classification system followed by classification symbols)							
U.S. : US CL: 435/69.1, 320.1; 935/25							
Documenta	tion searched other than minimum documentation to	the extent that such documents are include	d in the fields searched				
Electronic o	data base consulted during the international search	(name of data have and unhave amorially					
APS, DL		traine of data case and, where practicable	s, search terms used)				
	ms: systemic, cost protein, benthamiana, transgen	?, vector					
	CUMENTS CONSIDERED TO BE RELEVANT						
Category*	Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.				
<u>X</u> Y	The EMBO Journal, Volume 7, No. 6, issued J bacterial gene in plants mediated by infectious gentire document.	1 <u>-42</u> 43-44					
X,P	Proceedings of the National Academy of Science 1991, Donson et al, "Systemic expression of a b based vector", pages 7204-7208, see entire document	1 -44					
L	The EMBO Journal, Volume 7, No. 4, issued Apr of tomato golden mosaic virus: the coat protein symptom development", pages 899-904, see ent applicability).	1-42					
Y	US, A, 4,407,956 (Howell) 04 October 1983, sec	entire document.	1-42				
Y	EP, A, 0,278,667 (Ahlquist et al) 17 August 1988	1-42					
į							
1	•						
		·					
X Furthe	r documents are listed in the continuation of Box (C. See patent family annex.					
Spec	ial categories of cited documents:	"T" later document published after the inter	national filing date or priority				
A" docu to be	ment defining the general state of the art which is not considered part of particular relevance	data and not in conflict with the applicate principle or theory underlying the investigation.	ion but cited to understand the				
E" cartie	er document published on or after the international filing date	"X" document of particular relevance; the	claimed investion cannot be				
L" docu cited	ment which may throw doubts on priority chain(s) or which is to establish the publication date of another citation or other	considered novel or cannot be considered when the document is taken alone	ed to involve an inventive step				
speca	as remons (as apecused)	"Y" document of particular relevance; the considered to involve an inventive i	claimed invention cannot be				
)* docu	ment referring to an oral disclosure, use, exhibition or other	combined with one or more other such being obvious to a person skilled in the	documents, such combination				
documents of the pro-	most published prior to the international filing date but later than riorisy date claimed	*&* document member of the same patent fo	1				
ate of the ac	tual completion of the international search	Date of mailing of the international sear	ch report				
07 October 1992		27 OCT 1992					
ame and mailing address of the ISA/		Authorized officer					
Commissioner of Patents and Trademarks Box PCT		WV Ponce					
Washington, D.C. 20231 acsimile No. NOT APPLICABLE		P. RHODES Telephone N (703) 308-0196					
		e. e. 0000 8					

Form PCT/ISA/210 (second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US92/06359

	ntion). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim
Y	Becker et al, "Recombinant DNA Research and Viruses Cloning and Expression of Vira Genes", published 1985 by Martinus Nijhoff Publishing (MA), see pages 247-275, especially pages 264-267.	1-44
Y	Virology, Volume 177, issued August 1990, Beck et al, "Deletion of repeated sequences from tobacco mosaic virus mutants with two coat protein genes", pages 462-469, see entire document.	1-44
r	Virology, Volume 172, issued September 1989, Dawson et al, "A tobacco mosaic virus- hybrid expresses and loses an added gene", pages 285-292, see entire document.	1-44
	·	
	-	

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No. PCT/US92/06359

BOX II.	OBSERVATIONS WHERE UNITY OF INVENTION	WAS LACKING
	found multiple inventions as follows:	

- I. Claims 1-42, drawn to first vector and process of use, classified in Class 435, subclasses 69.1 and 320.1, for example.
 - II. Claim 43, drawn to a second vector, classified in Class 435, subclass 320.1, for example.

 III. Claim 44, drawn to a third vector, classified in Class 435, subclass 320.1, for example.
- III. Claim 44, drawn to a third vector, classified in Class 435, subclass 320.1, for example.

 The products of Groups I-III are separate and distinct inventions in that each is defined by a different nucleotide sequence and different expression properties and functions all of which constitute the special technical features which define the contribution of each invention. Since these special technical features are not shared by each product and since the common features do not establish an advance over the prior art, the inventions of Groups I-III do not share a technical relationship and do not form a single inventive concept within the meaning of Rule 13.2.

Form PCT/ISA/210 (extra sheet)(July 1992)*

04/11/2003, EAST Version: 1.03.0002